EP1077970A1 - 11-ARYL-BENZO B]NAPHTO 2,3-D]FURANES ET 11-ARYL-BENZO b]NAPHTO 2,3-d]THIOPHENES UTILES DANS LES TRAITEMENTS DE LA RESISTANCE INSULINIQUE ET DE L'HYPERGLYCEMIE - Google Patents
11-ARYL-BENZO B]NAPHTO 2,3-D]FURANES ET 11-ARYL-BENZO b]NAPHTO 2,3-d]THIOPHENES UTILES DANS LES TRAITEMENTS DE LA RESISTANCE INSULINIQUE ET DE L'HYPERGLYCEMIEInfo
- Publication number
- EP1077970A1 EP1077970A1 EP99922897A EP99922897A EP1077970A1 EP 1077970 A1 EP1077970 A1 EP 1077970A1 EP 99922897 A EP99922897 A EP 99922897A EP 99922897 A EP99922897 A EP 99922897A EP 1077970 A1 EP1077970 A1 EP 1077970A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- benzo
- naphtho
- carbon atoms
- thiophen
- bromo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 201000001421 hyperglycemia Diseases 0.000 title claims abstract description 11
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims description 27
- 206010022489 Insulin Resistance Diseases 0.000 title claims description 18
- 150000002240 furans Chemical class 0.000 title description 2
- 229930192474 thiophene Natural products 0.000 title description 2
- 150000003577 thiophenes Chemical class 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 770
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 404
- 150000001875 compounds Chemical class 0.000 claims abstract description 218
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 191
- 150000002367 halogens Chemical class 0.000 claims abstract description 188
- -1 nitro, amino Chemical group 0.000 claims abstract description 184
- 125000003118 aryl group Chemical group 0.000 claims abstract description 174
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 153
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 147
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 132
- 239000001257 hydrogen Substances 0.000 claims abstract description 116
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims abstract description 98
- 125000005163 aryl sulfanyl group Chemical group 0.000 claims abstract description 91
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract description 87
- 150000003839 salts Chemical class 0.000 claims abstract description 64
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims abstract description 25
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims abstract description 11
- 125000004104 aryloxy group Chemical group 0.000 claims abstract description 11
- YMRIDJQAEZFTSC-UHFFFAOYSA-N 2,3-dihydro-1h-tetrazole Chemical compound N1NC=NN1 YMRIDJQAEZFTSC-UHFFFAOYSA-N 0.000 claims abstract description 8
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 5
- 150000002431 hydrogen Chemical class 0.000 claims abstract 75
- 229910052717 sulfur Inorganic materials 0.000 claims description 204
- 229910052760 oxygen Inorganic materials 0.000 claims description 202
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 189
- 238000000034 method Methods 0.000 claims description 75
- 229910052794 bromium Inorganic materials 0.000 claims description 57
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 44
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 43
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 33
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N methyl cyanide Natural products CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 29
- 150000002148 esters Chemical class 0.000 claims description 28
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 28
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 23
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 22
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 21
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 20
- 239000008103 glucose Substances 0.000 claims description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 9
- 235000019260 propionic acid Nutrition 0.000 claims description 8
- 239000011734 sodium Chemical class 0.000 claims description 8
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- HERSKCAGZCXYMC-UHFFFAOYSA-N thiophen-3-ol Chemical compound OC=1C=CSC=1 HERSKCAGZCXYMC-UHFFFAOYSA-N 0.000 claims description 3
- HNKQMVOZECJOHN-XMMPIXPASA-N (2r)-2-[2,6-dibromo-4-(6-bromonaphtho[3,2-b][1]benzothiol-11-yl)phenoxy]-3-phenylpropanoic acid Chemical class C([C@H](C(=O)O)OC=1C(=CC(=CC=1Br)C=1C2=CC=CC=C2C(Br)=C2SC3=CC=CC=C3C2=1)Br)C1=CC=CC=C1 HNKQMVOZECJOHN-XMMPIXPASA-N 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- LJAAWLVJORFOEM-AREMUKBSSA-N (2r)-2-(2,6-dibromo-4-naphtho[3,2-b][1]benzothiol-11-ylphenoxy)-4-(1,3-dioxoisoindol-2-yl)butanoic acid Chemical compound C=1C=CC=C2C=1C=C1SC3=CC=CC=C3C1=C2C(C=C1Br)=CC(Br)=C1O[C@@H](C(=O)O)CCN1C(=O)C2=CC=CC=C2C1=O LJAAWLVJORFOEM-AREMUKBSSA-N 0.000 claims 1
- KXPOJKLAGFQEHI-CYBMUJFWSA-N (2r)-2-[2-bromo-5-(6-bromonaphtho[3,2-b][1]benzothiol-11-yl)phenoxy]propanoic acid Chemical compound C1=C(Br)C(O[C@H](C)C(O)=O)=CC(C=2C3=CC=CC=C3C(Br)=C3SC4=CC=CC=C4C3=2)=C1 KXPOJKLAGFQEHI-CYBMUJFWSA-N 0.000 claims 1
- NQYORHYEINNVLM-AREMUKBSSA-N (2r)-2-[4-(6-bromonaphtho[3,2-b][1]benzothiol-11-yl)phenoxy]-4-(1,3-dioxoisoindol-2-yl)butanoic acid Chemical compound C1=CC=C2C(C3=CC=C(C=C3)O[C@H](CCN3C(C4=CC=CC=C4C3=O)=O)C(=O)O)=C(C=3C(=CC=CC=3)S3)C3=C(Br)C2=C1 NQYORHYEINNVLM-AREMUKBSSA-N 0.000 claims 1
- CIURGNFHCVWAGL-CYBMUJFWSA-N (3r)-3-[2,6-dibromo-4-(6-bromonaphtho[3,2-b][1]benzothiol-11-yl)phenoxy]butanoic acid Chemical compound C1=C(Br)C(O[C@@H](CC(O)=O)C)=C(Br)C=C1C1=C(C=2C(=CC=CC=2)S2)C2=C(Br)C2=CC=CC=C12 CIURGNFHCVWAGL-CYBMUJFWSA-N 0.000 claims 1
- JLNAHODWHQEIQF-UHFFFAOYSA-N (4-naphtho[3,2-b][1]benzothiol-11-ylphenoxy)methylphosphonic acid Chemical compound C1=CC(OCP(O)(=O)O)=CC=C1C1=C2C3=CC=CC=C3SC2=CC2=CC=CC=C12 JLNAHODWHQEIQF-UHFFFAOYSA-N 0.000 claims 1
- COZBGFUHIPXOOR-UHFFFAOYSA-N 2,6-dibromo-4-(6-bromonaphtho[3,2-b][1]benzothiol-11-yl)phenol Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1=C(C=2C(=CC=CC=2)S2)C2=C(Br)C2=CC=CC=C12 COZBGFUHIPXOOR-UHFFFAOYSA-N 0.000 claims 1
- MGZQSVMOELAPKG-UHFFFAOYSA-N 2,6-dibromo-4-[6-(trifluoromethyl)naphtho[3,2-b][1]benzothiol-11-yl]phenol Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1=C2C3=CC=CC=C3SC2=C(C(F)(F)F)C2=CC=CC=C12 MGZQSVMOELAPKG-UHFFFAOYSA-N 0.000 claims 1
- WXIFBFSFIOCOFZ-UHFFFAOYSA-N 2-(2-cyano-4-naphtho[3,2-b][1]benzothiol-11-ylphenoxy)acetic acid Chemical compound C1=C(C#N)C(OCC(=O)O)=CC=C1C1=C2C3=CC=CC=C3SC2=CC2=CC=CC=C12 WXIFBFSFIOCOFZ-UHFFFAOYSA-N 0.000 claims 1
- VEIQAVBIDNIIRW-UHFFFAOYSA-N 2-[11-[4-(2-methoxy-2-oxoethoxy)phenyl]naphtho[3,2-b][1]benzothiol-8-yl]oxyacetic acid Chemical compound C1=CC(OCC(=O)OC)=CC=C1C1=C2C3=CC=CC=C3SC2=CC2=CC(OCC(O)=O)=CC=C12 VEIQAVBIDNIIRW-UHFFFAOYSA-N 0.000 claims 1
- RKKZNRQILHMAPY-UHFFFAOYSA-N 2-[2,6-dibromo-4-(6-bromonaphtho[3,2-b][1]benzothiol-11-yl)phenoxy]acetamide Chemical compound C1=C(Br)C(OCC(=O)N)=C(Br)C=C1C1=C2C3=CC=CC=C3SC2=C(Br)C2=CC=CC=C12 RKKZNRQILHMAPY-UHFFFAOYSA-N 0.000 claims 1
- FBTCFKHGAKUGNK-UHFFFAOYSA-N 2-[2,6-dimethyl-4-(6-methylnaphtho[3,2-b][1]benzothiol-11-yl)phenoxy]acetic acid Chemical compound CC1=C(OCC(O)=O)C(C)=CC(C=2C3=CC=CC=C3C(C)=C3C=2C2=CC=CC=C2S3)=C1 FBTCFKHGAKUGNK-UHFFFAOYSA-N 0.000 claims 1
- SOVAXKFEVHCVKA-UHFFFAOYSA-N 2-[3-(6-bromonaphtho[3,2-b][1]benzothiol-11-yl)phenoxy]acetic acid Chemical compound OC(=O)COC1=CC=CC(C=2C3=CC=CC=C3C(Br)=C3C=2C2=CC=CC=C2S3)=C1 SOVAXKFEVHCVKA-UHFFFAOYSA-N 0.000 claims 1
- GJGQWZZDGYNWLI-UHFFFAOYSA-N 2-[4-(6-bromonaphtho[3,2-b][1]benzothiol-11-yl)phenoxy]acetic acid Chemical compound C1=CC(OCC(=O)O)=CC=C1C1=C2C3=CC=CC=C3SC2=C(Br)C2=CC=CC=C12 GJGQWZZDGYNWLI-UHFFFAOYSA-N 0.000 claims 1
- OJUVQBPAQRSSFC-UHFFFAOYSA-N 2-hydroxy-5-naphtho[3,2-b][1]benzothiol-11-ylbenzene-1,3-dicarbonitrile Chemical compound C1=C(C#N)C(O)=C(C#N)C=C1C1=C2C3=CC=CC=C3SC2=CC2=CC=CC=C12 OJUVQBPAQRSSFC-UHFFFAOYSA-N 0.000 claims 1
- PCVAUOPOEQOHOG-UHFFFAOYSA-N 2-methoxy-5-naphtho[3,2-b][1]benzothiol-11-ylbenzene-1,3-dicarbonitrile Chemical compound C1=C(C#N)C(OC)=C(C#N)C=C1C1=C2C3=CC=CC=C3SC2=CC2=CC=CC=C12 PCVAUOPOEQOHOG-UHFFFAOYSA-N 0.000 claims 1
- XBUYJFBQQZOAAH-UHFFFAOYSA-N 3-(6-bromonaphtho[3,2-b][1]benzothiol-11-yl)-2,6-difluorophenol Chemical compound OC1=C(F)C=CC(C=2C3=CC=CC=C3C(Br)=C3C=2C2=CC=CC=C2S3)=C1F XBUYJFBQQZOAAH-UHFFFAOYSA-N 0.000 claims 1
- VYIBCOSBNVFEIW-UHFFFAOYSA-N 3-phenylpropanamide Chemical compound NC(=O)CCC1=CC=CC=C1 VYIBCOSBNVFEIW-UHFFFAOYSA-N 0.000 claims 1
- UOZNEKDHGHDYJY-UHFFFAOYSA-N 4-(6-iodonaphtho[3,2-b][1]benzothiol-11-yl)phenol Chemical compound C1=CC(O)=CC=C1C1=C(C=2C(=CC=CC=2)S2)C2=C(I)C2=CC=CC=C12 UOZNEKDHGHDYJY-UHFFFAOYSA-N 0.000 claims 1
- LHHHMLQHNYPPCH-UHFFFAOYSA-N 4-(6-methoxynaphtho[3,2-b][1]benzothiol-11-yl)phenol Chemical compound C12=CC=CC=C2C(OC)=C2SC3=CC=CC=C3C2=C1C1=CC=C(O)C=C1 LHHHMLQHNYPPCH-UHFFFAOYSA-N 0.000 claims 1
- JDKYAHJHPSLEMU-UHFFFAOYSA-N 4-[6-(trifluoromethyl)naphtho[3,2-b][1]benzothiol-11-yl]phenol Chemical compound C1=CC(O)=CC=C1C1=C(C=2C(=CC=CC=2)S2)C2=C(C(F)(F)F)C2=CC=CC=C12 JDKYAHJHPSLEMU-UHFFFAOYSA-N 0.000 claims 1
- SZNFAVDFBPCZOV-UHFFFAOYSA-N 4-[6-[2-(dimethylamino)ethylsulfanyl]naphtho[3,2-b][1]benzothiol-11-yl]phenol Chemical compound C12=CC=CC=C2C(SCCN(C)C)=C2SC3=CC=CC=C3C2=C1C1=CC=C(O)C=C1 SZNFAVDFBPCZOV-UHFFFAOYSA-N 0.000 claims 1
- AAKFITBFFSRCBJ-UHFFFAOYSA-N 4-naphtho[3,2-b][1]benzothiol-11-ylbenzene-1,2-diol Chemical compound C1=C(O)C(O)=CC=C1C1=C2C3=CC=CC=C3SC2=CC2=CC=CC=C12 AAKFITBFFSRCBJ-UHFFFAOYSA-N 0.000 claims 1
- IPEMCIBPDYCJLO-UHFFFAOYSA-N 5-[(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)methyl]-n-(2,4,6-trimethoxyphenyl)furan-2-carboxamide Chemical compound COC1=CC(OC)=CC(OC)=C1NC(=O)C(O1)=CC=C1CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C IPEMCIBPDYCJLO-UHFFFAOYSA-N 0.000 claims 1
- DYLRCWMPCHZHDX-UHFFFAOYSA-N 8-methoxy-11-(4-methoxyphenyl)naphtho[2,3-b][1]benzothiole Chemical compound C1=CC(OC)=CC=C1C1=C2C3=CC=CC=C3SC2=CC2=CC(OC)=CC=C12 DYLRCWMPCHZHDX-UHFFFAOYSA-N 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 1
- YEWZQCDRZRYAEB-UHFFFAOYSA-N ditert-butyl hydrogen phosphate Chemical compound CC(C)(C)OP(O)(=O)OC(C)(C)C YEWZQCDRZRYAEB-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960001867 guaiacol Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- CMQUPDOCZFIMPB-UHFFFAOYSA-N methyl 2-[2,6-dibromo-4-(6-bromonaphtho[3,2-b][1]benzothiol-11-yl)phenoxy]acetate Chemical compound C1=C(Br)C(OCC(=O)OC)=C(Br)C=C1C1=C2C3=CC=CC=C3SC2=C(Br)C2=CC=CC=C12 CMQUPDOCZFIMPB-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229960003424 phenylacetic acid Drugs 0.000 claims 1
- 239000003279 phenylacetic acid Substances 0.000 claims 1
- 229940080818 propionamide Drugs 0.000 claims 1
- 239000001384 succinic acid Substances 0.000 claims 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 abstract description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 250
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 216
- 239000007787 solid Substances 0.000 description 151
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 136
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 126
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 121
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 117
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 103
- 239000002904 solvent Substances 0.000 description 96
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 94
- 229910002092 carbon dioxide Inorganic materials 0.000 description 83
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 75
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 72
- 239000000243 solution Substances 0.000 description 65
- 229960000583 acetic acid Drugs 0.000 description 63
- 239000011541 reaction mixture Substances 0.000 description 61
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 48
- 230000000694 effects Effects 0.000 description 47
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 46
- 235000011054 acetic acid Nutrition 0.000 description 45
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 40
- 239000000203 mixture Substances 0.000 description 37
- 239000003208 petroleum Substances 0.000 description 37
- 239000000741 silica gel Substances 0.000 description 36
- 229910002027 silica gel Inorganic materials 0.000 description 36
- 239000002156 adsorbate Substances 0.000 description 35
- 150000002989 phenols Chemical class 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 31
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 31
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 28
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 28
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 28
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 description 28
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 26
- 239000000725 suspension Substances 0.000 description 26
- 229910000027 potassium carbonate Inorganic materials 0.000 description 25
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 239000012267 brine Substances 0.000 description 23
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 23
- 239000002253 acid Substances 0.000 description 22
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 21
- 239000003153 chemical reaction reagent Substances 0.000 description 21
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 20
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 20
- 206010012601 diabetes mellitus Diseases 0.000 description 19
- 239000003921 oil Substances 0.000 description 19
- 239000012071 phase Substances 0.000 description 19
- 239000003480 eluent Substances 0.000 description 18
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 18
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 17
- 239000012299 nitrogen atmosphere Substances 0.000 description 17
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 17
- 239000006184 cosolvent Substances 0.000 description 16
- 229910052740 iodine Inorganic materials 0.000 description 16
- 150000004702 methyl esters Chemical class 0.000 description 16
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- 238000006751 Mitsunobu reaction Methods 0.000 description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 15
- 239000002585 base Substances 0.000 description 15
- 239000000460 chlorine Substances 0.000 description 15
- 235000002639 sodium chloride Nutrition 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 102000004877 Insulin Human genes 0.000 description 14
- 108090001061 Insulin Proteins 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 14
- 229940125396 insulin Drugs 0.000 description 14
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 14
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 14
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 13
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 13
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 13
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 102000003746 Insulin Receptor Human genes 0.000 description 12
- 108010001127 Insulin Receptor Proteins 0.000 description 12
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 12
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 239000003880 polar aprotic solvent Substances 0.000 description 12
- 230000009466 transformation Effects 0.000 description 12
- 229910052801 chlorine Inorganic materials 0.000 description 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 10
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 10
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 9
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 9
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 9
- 150000008041 alkali metal carbonates Chemical class 0.000 description 9
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 8
- SODQFLRLAOALCF-UHFFFAOYSA-N 1lambda3-bromacyclohexa-1,3,5-triene Chemical compound Br1=CC=CC=C1 SODQFLRLAOALCF-UHFFFAOYSA-N 0.000 description 8
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 8
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 150000001735 carboxylic acids Chemical class 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 239000012442 inert solvent Substances 0.000 description 8
- KJRCEJOSASVSRA-UHFFFAOYSA-N propane-2-thiol Chemical compound CC(C)S KJRCEJOSASVSRA-UHFFFAOYSA-N 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 8
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical class OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 7
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 229910052786 argon Inorganic materials 0.000 description 7
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 7
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 7
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 229910052763 palladium Inorganic materials 0.000 description 7
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Substances [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000012552 review Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000010998 test method Methods 0.000 description 7
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 6
- 239000005711 Benzoic acid Substances 0.000 description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- 239000002841 Lewis acid Substances 0.000 description 6
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 6
- 208000008589 Obesity Diseases 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 6
- 235000010233 benzoic acid Nutrition 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 230000017858 demethylation Effects 0.000 description 6
- 238000010520 demethylation reaction Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000012259 ether extract Substances 0.000 description 6
- 239000011630 iodine Substances 0.000 description 6
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 6
- 150000007517 lewis acids Chemical class 0.000 description 6
- 229910052744 lithium Inorganic materials 0.000 description 6
- 230000003228 microsomal effect Effects 0.000 description 6
- UWMISBRPSJFHIR-UHFFFAOYSA-N naphtho[2,3-b][1]benzothiole Chemical class C1=CC=C2C=C3C4=CC=CC=C4SC3=CC2=C1 UWMISBRPSJFHIR-UHFFFAOYSA-N 0.000 description 6
- 150000002825 nitriles Chemical class 0.000 description 6
- 235000020824 obesity Nutrition 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 6
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 6
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 6
- 238000000844 transformation Methods 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- CHZCERSEMVWNHL-UHFFFAOYSA-N 2-hydroxybenzonitrile Chemical class OC1=CC=CC=C1C#N CHZCERSEMVWNHL-UHFFFAOYSA-N 0.000 description 5
- 229930185605 Bisphenol Natural products 0.000 description 5
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 5
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000010949 copper Substances 0.000 description 5
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 5
- 238000006209 dephosphorylation reaction Methods 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 239000002024 ethyl acetate extract Substances 0.000 description 5
- 125000004494 ethyl ester group Chemical group 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 5
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 5
- 201000008980 hyperinsulinism Diseases 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- FTMRMQALUDDFQO-UHFFFAOYSA-N naphtho[2,3-b][1]benzofuran Chemical class C1=CC=C2C=C3C4=CC=CC=C4OC3=CC2=C1 FTMRMQALUDDFQO-UHFFFAOYSA-N 0.000 description 5
- 235000011056 potassium acetate Nutrition 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 238000007363 ring formation reaction Methods 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 229910052727 yttrium Inorganic materials 0.000 description 5
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 5
- ICSJVDUSLIMVNZ-UHFFFAOYSA-N 2-benzyl-1-benzothiophene Chemical compound C=1C2=CC=CC=C2SC=1CC1=CC=CC=C1 ICSJVDUSLIMVNZ-UHFFFAOYSA-N 0.000 description 4
- VPWNQTHUCYMVMZ-UHFFFAOYSA-N 4,4'-sulfonyldiphenol Chemical class C1=CC(O)=CC=C1S(=O)(=O)C1=CC=C(O)C=C1 VPWNQTHUCYMVMZ-UHFFFAOYSA-N 0.000 description 4
- 229910015900 BF3 Inorganic materials 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 241000907663 Siproeta stelenes Species 0.000 description 4
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 4
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000010933 acylation Effects 0.000 description 4
- 238000005917 acylation reaction Methods 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 4
- 238000005893 bromination reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(i) oxide Chemical compound [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 4
- 150000005690 diesters Chemical class 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 150000008282 halocarbons Chemical class 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- LSDPWZHWYPCBBB-UHFFFAOYSA-N methyl mercaptane Natural products SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 4
- 150000002828 nitro derivatives Chemical class 0.000 description 4
- 125000001979 organolithium group Chemical group 0.000 description 4
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 4
- 150000003459 sulfonic acid esters Chemical class 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- ORHZATAMUZWDOQ-UHFFFAOYSA-N (6-methoxy-1-benzothiophen-2-yl)-phenylmethanol Chemical compound S1C2=CC(OC)=CC=C2C=C1C(O)C1=CC=CC=C1 ORHZATAMUZWDOQ-UHFFFAOYSA-N 0.000 description 3
- ACZFBYCNAVEFLC-YFKPBYRVSA-N (S)-3-(imidazol-5-yl)lactic acid Chemical compound OC(=O)[C@@H](O)CC1=CN=CN1 ACZFBYCNAVEFLC-YFKPBYRVSA-N 0.000 description 3
- NQALVSDQVZVGEZ-UHFFFAOYSA-N 1-benzothiophen-2-yl-(3-methoxyphenyl)methanol Chemical compound COC1=CC=CC(C(O)C=2SC3=CC=CC=C3C=2)=C1 NQALVSDQVZVGEZ-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 208000002705 Glucose Intolerance Diseases 0.000 description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- 239000012455 biphasic mixture Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 238000007333 cyanation reaction Methods 0.000 description 3
- 230000030609 dephosphorylation Effects 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 125000004185 ester group Chemical group 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000011968 lewis acid catalyst Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 3
- 150000003009 phosphonic acids Chemical class 0.000 description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 description 3
- 235000011009 potassium phosphates Nutrition 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 150000003138 primary alcohols Chemical class 0.000 description 3
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 3
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 235000011150 stannous chloride Nutrition 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- WMGWLIAIMDFMIQ-UHFFFAOYSA-N sulfuroiodidic acid Chemical class OS(I)(=O)=O WMGWLIAIMDFMIQ-UHFFFAOYSA-N 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- ZGIKZRRIYSKUEA-UHFFFAOYSA-N (2-benzyl-1-benzothiophen-3-yl)-(3,4-dimethoxyphenyl)methanone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)C(C1=CC=CC=C1S1)=C1CC1=CC=CC=C1 ZGIKZRRIYSKUEA-UHFFFAOYSA-N 0.000 description 2
- XJISXAHLSVAVLK-UHFFFAOYSA-N (2-benzyl-1-benzothiophen-3-yl)-(3-methoxyphenyl)methanone Chemical compound COC1=CC=CC(C(=O)C=2C3=CC=CC=C3SC=2CC=2C=CC=CC=2)=C1 XJISXAHLSVAVLK-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- FNAKEOXYWBWIRT-UHFFFAOYSA-N 2,3-dibromophenol Chemical class OC1=CC=CC(Br)=C1Br FNAKEOXYWBWIRT-UHFFFAOYSA-N 0.000 description 2
- YPJVJVIQWWXEHO-UHFFFAOYSA-N 2,3-diiodophenol Chemical compound OC1=CC=CC(I)=C1I YPJVJVIQWWXEHO-UHFFFAOYSA-N 0.000 description 2
- BSWWXRFVMJHFBN-UHFFFAOYSA-N 2,4,6-tribromophenol Chemical compound OC1=C(Br)C=C(Br)C=C1Br BSWWXRFVMJHFBN-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- XGILAAMKEQUXLS-JTQLQIEISA-N 3-(indol-3-yl) lactate Chemical compound C1=CC=C2C(C[C@H](O)C(O)=O)=CNC2=C1 XGILAAMKEQUXLS-JTQLQIEISA-N 0.000 description 2
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 2
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- VSMDINRNYYEDRN-UHFFFAOYSA-N 4-iodophenol Chemical compound OC1=CC=C(I)C=C1 VSMDINRNYYEDRN-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 2
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- VOXXWSYKYCBWHO-UHFFFAOYSA-N HO-Phe-OH Natural products OC(=O)C(O)CC1=CC=CC=C1 VOXXWSYKYCBWHO-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- KYOIPUDHYRWSFO-UHFFFAOYSA-N [Br].[Li] Chemical group [Br].[Li] KYOIPUDHYRWSFO-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000011609 ammonium molybdate Substances 0.000 description 2
- 229940010552 ammonium molybdate Drugs 0.000 description 2
- 239000012378 ammonium molybdate tetrahydrate Substances 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 238000005899 aromatization reaction Methods 0.000 description 2
- 150000001543 aryl boronic acids Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- FIXLYHHVMHXSCP-UHFFFAOYSA-H azane;dihydroxy(dioxo)molybdenum;trioxomolybdenum;tetrahydrate Chemical compound N.N.N.N.N.N.O.O.O.O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O[Mo](O)(=O)=O.O[Mo](O)(=O)=O.O[Mo](O)(=O)=O FIXLYHHVMHXSCP-UHFFFAOYSA-H 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000012320 chlorinating reagent Substances 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 150000001879 copper Chemical class 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- USQBBPIGNSWXPQ-UHFFFAOYSA-N dibromo(dibromomethoxy)methane Chemical compound BrC(Br)OC(Br)Br USQBBPIGNSWXPQ-UHFFFAOYSA-N 0.000 description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 description 2
- 239000002027 dichloromethane extract Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 2
- VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000002083 iodinating effect Effects 0.000 description 2
- 208000023589 ischemic disease Diseases 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940107698 malachite green Drugs 0.000 description 2
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 description 2
- QJQYPZZUKLQGGT-UHFFFAOYSA-N methyl hypobromite Chemical compound COBr QJQYPZZUKLQGGT-UHFFFAOYSA-N 0.000 description 2
- XVDFTPMOHNLNCB-UHFFFAOYSA-N methyl hypoiodite Chemical class COI XVDFTPMOHNLNCB-UHFFFAOYSA-N 0.000 description 2
- 239000012022 methylating agents Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 2
- 229950009215 phenylbutanoic acid Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 238000011808 rodent model Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 125000000542 sulfonic acid group Chemical group 0.000 description 2
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical class OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- VXKWYPOMXBVZSJ-UHFFFAOYSA-N tetramethyltin Chemical compound C[Sn](C)(C)C VXKWYPOMXBVZSJ-UHFFFAOYSA-N 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- PMVKQOBZPDBCSP-UHFFFAOYSA-N (2-benzyl-1-benzothiophen-3-yl)-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C(C1=CC=CC=C1S1)=C1CC1=CC=CC=C1 PMVKQOBZPDBCSP-UHFFFAOYSA-N 0.000 description 1
- GWRPGRLGKRAWJH-UHFFFAOYSA-N (2-benzyl-1-benzothiophen-3-yl)-[4-methoxy-3,5-di(propan-2-yl)phenyl]methanone Chemical compound C1=C(C(C)C)C(OC)=C(C(C)C)C=C1C(=O)C(C1=CC=CC=C1S1)=C1CC1=CC=CC=C1 GWRPGRLGKRAWJH-UHFFFAOYSA-N 0.000 description 1
- VZCIZQRKHPAUHK-UHFFFAOYSA-N (2-benzyl-6-methoxy-1-benzothiophen-3-yl)-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C(C1=CC=C(OC)C=C1S1)=C1CC1=CC=CC=C1 VZCIZQRKHPAUHK-UHFFFAOYSA-N 0.000 description 1
- ALSBEXLUMDNYTN-HNNXBMFYSA-N (2s)-2-(4-nitrobenzoyl)-4-phenylbutanoic acid Chemical compound C([C@H](C(=O)O)C(=O)C=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 ALSBEXLUMDNYTN-HNNXBMFYSA-N 0.000 description 1
- MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 1
- GEJFGWDZUISYRY-JTQLQIEISA-N (2s)-2-hydroxy-4-(3-oxo-1h-isoindol-2-yl)butanoic acid Chemical compound C1=CC=C2C(=O)N(CC[C@H](O)C(O)=O)CC2=C1 GEJFGWDZUISYRY-JTQLQIEISA-N 0.000 description 1
- YWDXODQRCDEZLN-VIFPVBQESA-N (2s)-4-(1,3-dioxoisoindol-2-yl)-2-hydroxybutanoic acid Chemical compound C1=CC=C2C(=O)N(CC[C@H](O)C(O)=O)C(=O)C2=C1 YWDXODQRCDEZLN-VIFPVBQESA-N 0.000 description 1
- VOXXWSYKYCBWHO-MRVPVSSYSA-N (R)-3-phenyllactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=CC=C1 VOXXWSYKYCBWHO-MRVPVSSYSA-N 0.000 description 1
- VOXXWSYKYCBWHO-QMMMGPOBSA-N (S)-3-phenyllactic acid Chemical compound OC(=O)[C@@H](O)CC1=CC=CC=C1 VOXXWSYKYCBWHO-QMMMGPOBSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 150000000180 1,2-diols Chemical class 0.000 description 1
- ZKSOJQDNSNJIQW-UHFFFAOYSA-N 1-(bromomethyl)-3-methoxybenzene Chemical compound COC1=CC=CC(CBr)=C1 ZKSOJQDNSNJIQW-UHFFFAOYSA-N 0.000 description 1
- ILMXGRVAPAQFTQ-UHFFFAOYSA-N 1-benzothiophen-2-yl(phenyl)methanol Chemical compound C=1C2=CC=CC=C2SC=1C(O)C1=CC=CC=C1 ILMXGRVAPAQFTQ-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- FHTDDANQIMVWKZ-UHFFFAOYSA-N 1h-pyridine-4-thione Chemical compound SC1=CC=NC=C1 FHTDDANQIMVWKZ-UHFFFAOYSA-N 0.000 description 1
- VGVRPFIJEJYOFN-UHFFFAOYSA-N 2,3,4,6-tetrachlorophenol Chemical class OC1=C(Cl)C=C(Cl)C(Cl)=C1Cl VGVRPFIJEJYOFN-UHFFFAOYSA-N 0.000 description 1
- UMPSXRYVXUPCOS-UHFFFAOYSA-N 2,3-dichlorophenol Chemical class OC1=CC=CC(Cl)=C1Cl UMPSXRYVXUPCOS-UHFFFAOYSA-N 0.000 description 1
- XXKHDSGLCLCFSC-UHFFFAOYSA-N 2,3-diphenylphenol Chemical class C=1C=CC=CC=1C=1C(O)=CC=CC=1C1=CC=CC=C1 XXKHDSGLCLCFSC-UHFFFAOYSA-N 0.000 description 1
- KWLIGHXPUYUTBH-UHFFFAOYSA-N 2,4-difluoro-3-methoxybenzoic acid Chemical compound COC1=C(F)C=CC(C(O)=O)=C1F KWLIGHXPUYUTBH-UHFFFAOYSA-N 0.000 description 1
- TVPDDKXZHKJUPX-UHFFFAOYSA-N 2-(cyanomethoxy)acetonitrile Chemical compound N#CCOCC#N TVPDDKXZHKJUPX-UHFFFAOYSA-N 0.000 description 1
- PACPJYRUCIRQSL-UHFFFAOYSA-N 2-(dicyanomethoxy)propanedinitrile Chemical compound N#CC(C#N)OC(C#N)C#N PACPJYRUCIRQSL-UHFFFAOYSA-N 0.000 description 1
- QMBTYRVDXVKWJM-UHFFFAOYSA-N 2-[(3-methoxyphenyl)methyl]-1-benzothiophene Chemical compound COC1=CC=CC(CC=2SC3=CC=CC=C3C=2)=C1 QMBTYRVDXVKWJM-UHFFFAOYSA-N 0.000 description 1
- LIOZOBVITISTGK-UHFFFAOYSA-N 2-[2,6-dibromo-4-(6-bromonaphtho[3,2-b][1]benzothiol-11-yl)phenoxy]-3-pyridin-3-ylpropanoic acid Chemical compound BrC=1C=C(C=2C3=CC=CC=C3C(Br)=C3SC4=CC=CC=C4C3=2)C=C(Br)C=1OC(C(=O)O)CC1=CC=CN=C1 LIOZOBVITISTGK-UHFFFAOYSA-N 0.000 description 1
- BOOMNQMMZXXWGF-UHFFFAOYSA-N 2-[2,6-dibromo-4-(6-bromonaphtho[3,2-b][1]benzothiol-11-yl)phenoxy]acetic acid Chemical compound C1=C(Br)C(OCC(=O)O)=C(Br)C=C1C1=C2C3=CC=CC=C3SC2=C(Br)C2=CC=CC=C12 BOOMNQMMZXXWGF-UHFFFAOYSA-N 0.000 description 1
- MIZFACCZBNAWSM-UHFFFAOYSA-N 2-benzyl-6-methoxy-1-benzothiophene Chemical compound S1C2=CC(OC)=CC=C2C=C1CC1=CC=CC=C1 MIZFACCZBNAWSM-UHFFFAOYSA-N 0.000 description 1
- KQDJTBPASNJQFQ-UHFFFAOYSA-N 2-iodophenol Chemical class OC1=CC=CC=C1I KQDJTBPASNJQFQ-UHFFFAOYSA-N 0.000 description 1
- FSTPMFASNVISBU-UHFFFAOYSA-N 2-methoxybenzonitrile Chemical compound COC1=CC=CC=C1C#N FSTPMFASNVISBU-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- VIOBGCWEHLRBEP-UHFFFAOYSA-N 3,4-dimethoxybenzoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1OC VIOBGCWEHLRBEP-UHFFFAOYSA-N 0.000 description 1
- XDXPTWCKKOEWIN-UHFFFAOYSA-N 3-hydroxybenzene-1,2-dicarbonitrile Chemical class OC1=CC=CC(C#N)=C1C#N XDXPTWCKKOEWIN-UHFFFAOYSA-N 0.000 description 1
- WMPDAIZRQDCGFH-UHFFFAOYSA-N 3-methoxybenzaldehyde Chemical compound COC1=CC=CC(C=O)=C1 WMPDAIZRQDCGFH-UHFFFAOYSA-N 0.000 description 1
- RUQIUASLAXJZIE-UHFFFAOYSA-N 3-methoxybenzoyl chloride Chemical compound COC1=CC=CC(C(Cl)=O)=C1 RUQIUASLAXJZIE-UHFFFAOYSA-N 0.000 description 1
- QNJVELOLCDKQBN-UHFFFAOYSA-N 4-bromo-2,6-di(propan-2-yl)phenol Chemical compound CC(C)C1=CC(Br)=CC(C(C)C)=C1O QNJVELOLCDKQBN-UHFFFAOYSA-N 0.000 description 1
- BFQSQUAVMNHOEF-UHFFFAOYSA-N 4-bromo-2,6-difluoroaniline Chemical compound NC1=C(F)C=C(Br)C=C1F BFQSQUAVMNHOEF-UHFFFAOYSA-N 0.000 description 1
- MLANVLHDLMMQGQ-UHFFFAOYSA-N 4-bromo-5-(6-bromonaphtho[3,2-b][1]benzothiol-11-yl)benzene-1,2-diol Chemical compound C1=C(O)C(O)=CC(Br)=C1C1=C(C=2C(=CC=CC=2)S2)C2=C(Br)C2=CC=CC=C12 MLANVLHDLMMQGQ-UHFFFAOYSA-N 0.000 description 1
- IIDVLGKHIXHIMH-UHFFFAOYSA-N 4-methoxy-3,5-di(propan-2-yl)benzoic acid Chemical compound COC1=C(C(C)C)C=C(C(O)=O)C=C1C(C)C IIDVLGKHIXHIMH-UHFFFAOYSA-N 0.000 description 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 1
- KRBBGMOONSUDGO-UHFFFAOYSA-N 5-bromo-1,3-thiazolidine-2,4-dione Chemical compound BrC1SC(=O)NC1=O KRBBGMOONSUDGO-UHFFFAOYSA-N 0.000 description 1
- PPBFJCWDVJEYCW-UHFFFAOYSA-N 5-bromo-2-methoxy-1,3-di(propan-2-yl)benzene Chemical compound COC1=C(C(C)C)C=C(Br)C=C1C(C)C PPBFJCWDVJEYCW-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- XYAMQJRTGJRPFG-UHFFFAOYSA-N COC1=CC=CC(C=O)=C1.COC1=CC=CC=C1C=O Chemical compound COC1=CC=CC(C=O)=C1.COC1=CC=CC=C1C=O XYAMQJRTGJRPFG-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910018828 PO3H2 Inorganic materials 0.000 description 1
- NMPPJJIBQQCOOI-UHFFFAOYSA-N Papuline Natural products COC(=O)C(O)CC1=CC=CC=C1 NMPPJJIBQQCOOI-UHFFFAOYSA-N 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108090000244 Rat Proteins Proteins 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- GDRABJKREORCGG-UHFFFAOYSA-N [2,6-dibromo-4-(6-bromonaphtho[3,2-b][1]benzothiol-11-yl)phenoxy]methylphosphonic acid Chemical compound C1=C(Br)C(OCP(O)(=O)O)=C(Br)C=C1C1=C(C=2C(=CC=CC=2)S2)C2=C(Br)C2=CC=CC=C12 GDRABJKREORCGG-UHFFFAOYSA-N 0.000 description 1
- JNVCSEDACVAATK-UHFFFAOYSA-L [Ca+2].[S-]SSS[S-] Chemical compound [Ca+2].[S-]SSS[S-] JNVCSEDACVAATK-UHFFFAOYSA-L 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- UAMZETBJZRERCQ-UHFFFAOYSA-N alpha-aminopropionitrile Chemical compound CC(N)C#N UAMZETBJZRERCQ-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 150000001504 aryl thiols Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- UAZDIGCOBKKMPU-UHFFFAOYSA-O azanium;azide Chemical compound [NH4+].[N-]=[N+]=[N-] UAZDIGCOBKKMPU-UHFFFAOYSA-O 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- JBIKOPZNNQPZLH-UHFFFAOYSA-N bis(trifluoromethyl)mercury Chemical compound FC(F)(F)[Hg]C(F)(F)F JBIKOPZNNQPZLH-UHFFFAOYSA-N 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 108010086192 chymostatin Proteins 0.000 description 1
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 1
- 229950009226 ciglitazone Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 150000001907 coumarones Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- ZJYKSSGYDPNKQS-LLVKDONJSA-N ethyl (2r)-2-hydroxy-4-phenylbutanoate Chemical compound CCOC(=O)[C@H](O)CCC1=CC=CC=C1 ZJYKSSGYDPNKQS-LLVKDONJSA-N 0.000 description 1
- GXWQBFURCBCQJW-UHFFFAOYSA-N ethyl 3-pyridin-3-ylpropanoate Chemical compound CCOC(=O)CCC1=CC=CN=C1 GXWQBFURCBCQJW-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(3+);trinitrate Chemical compound [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- NRVFDGZJTPCULU-UHFFFAOYSA-N meda Chemical compound Cl.CN(C)CCS NRVFDGZJTPCULU-UHFFFAOYSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- NMPPJJIBQQCOOI-VIFPVBQESA-N methyl (2s)-2-hydroxy-3-phenylpropanoate Chemical compound COC(=O)[C@@H](O)CC1=CC=CC=C1 NMPPJJIBQQCOOI-VIFPVBQESA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- YFCUZWYIPBUQBD-ZOWNYOTGSA-N n-[(3s)-7-amino-1-chloro-2-oxoheptan-3-yl]-4-methylbenzenesulfonamide;hydron;chloride Chemical compound Cl.CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 YFCUZWYIPBUQBD-ZOWNYOTGSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 150000003858 primary carboxamides Chemical group 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000027404 regulation of phosphorylation Effects 0.000 description 1
- 102220305863 rs1015663503 Human genes 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- VLHOVNZJTJUSQU-UHFFFAOYSA-M sodium;carbonofluoridate Chemical compound [Na+].[O-]C(F)=O VLHOVNZJTJUSQU-UHFFFAOYSA-M 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ZXUCBXRTRRIBSO-UHFFFAOYSA-L tetrabutylazanium;sulfate Chemical compound [O-]S([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC ZXUCBXRTRRIBSO-UHFFFAOYSA-L 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- KTESRQWGRCVGEJ-UHFFFAOYSA-N trifluoromethylmercury Chemical compound FC(F)(F)[Hg] KTESRQWGRCVGEJ-UHFFFAOYSA-N 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/74—Naphthothiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Definitions
- Hyperinsulinemia can be present as a result of insulin resistance, such as is in obese and/or diabetic (NIDDM) subjects and/or glucose intolerant subjects, or in IDDM subjects, as a consequence of over injection of insulin compared with normal physiological release of the hormone by the endocrine pancreas.
- NIDDM diabetic diabetic
- hyperinsulinemia with obesity and with ischemic diseases of the large blood vessels (e.g. atherosclerosis) has been well established by numerous experimental, clinical and epidemiological studies (summarized by Stout, Metabolism 1985, 34, 1, and in more detail by Pyorala et al, Diabetes/Metabolism Reviews 1987, 3, 463). Statistically significant plasma insulin elevations at 1 and 2 hours after oral glucose load correlates with an increased risk of coronary heart disease.
- the independent risk factors obesity and hypertension for atherosclerotic diseases are also associated with insulin resistance.
- insulin resistance is located in peripheral tissues (principally muscle) and correlates directly with the severity of hypertension (DeFronzo and Ferrannini, Diabetes Care 1991, 14, 173).
- insulin resistance generates hyperinsulinemia, which is recruited as a mechanism to limit further weight gain via thermogenesis, but insulin also increases renal sodium reabsorption and stimulates the sympathetic nervous system in kidneys, heart, and vasculature, creating hypertension.
- insulin resistance is usually the result of a defect in the insulin receptor signaling system, at a site post binding of insulin to the receptor.
- Accumulated scientific evidence demonstrating insulin resistance in the major tissues which respond to insulin strongly suggests that a defect in insulin signal transduction resides at an early step in this cascade, specifically at the insulin receptor kinase activity, which appears to be diminished (reviewed by Haring, Diabetalogia 1991, 34, 848).
- Protein-tyrosine phosphatases (PTPases) play an important role in the regulation of phosphorylation of proteins.
- PTPases dephosphorylate the activated insulin receptor, attenuating the tyrosine kinase activity. PTPases can also modulate post- receptor signaling by catalyzing the dephosphorylation of cellular substrates of the insulin receptor kinase.
- the enzymes that appear most likely to closely associate with the insulin receptor and therefore, most likely to regulate the insulin receptor kinase activity, include PTP1B, LAR, PTPoc and SH-PTP2 (B. J. Goldstein, J. Cellular Biochemistry 1992, 48, 33; B. J.
- This invention provides a compound of formula I having the structure
- B and D are each, independently, hydrogen, halogen, CN, alkyl of 1-6 carbon atoms, aryl, aralkyl of 6-12 carbon atoms, nitro, amino or OR;
- R is hydrogen, alkyl of 1-6 carbon atoms, -COR 1 , -CH 2 CO2R 1 , -CH(R la )CO 2 R 1 , or
- R 1 and R la are each, independently, hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 6-12 carbon atoms or aryl; E is S, SO, SO 2 , O;
- X is hydrogen, halogen, alkyl of 1-6 carbon atoms, CN, perfluoroalkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, aryloxy, arylalkoxy of 6-12 carbon atoms, nitro, amino, alkylsulfanyl of 1-6 carbon atoms, arylsulfanyl, pyridylsulfanyl, 2-N,N-dimethylaminoethylsulfanyl, or -OCH 2 CO 2 R lb ;
- R lb is hydrogen or alkyl of 1-6 carbon atoms
- Y and Z are each, independently, hydrogen or OR 2
- R is hydrogen, alkyl of 1-6 carbon atoms, aralkyl of 6-12 carbon atoms, or
- R 3 is hydrogen or alkyl of 1-6 carbon atoms
- C is hydrogen, halogen or OR 4
- R 4 is hydrogen, alkyl of 1-6 carbon atoms, -CH(R 5 )W, -C(CH 3 ) 2 CO 2 R 6 ,
- R 5 is hydrogen, alkyl of 1-6 carbon atoms, aralkyl, aryl, CH 2 (lH-imidazol-4-yl), -CH 2 (3- 1 H-indolyl), -CH 2 CH 2 ( 1 ,3-dioxo- 1 ,3-dihydro-isoindol-2-yl),
- W is -CO 2 R 6 , -CONH 2 , -CONHOH, CN, -CONH(CH 2 ) 2 CN, 5-tetrazole, -PO 3 (R 6 ) 2 , -CH 2 OH, or -CH 2 Br, -CONR 6 CHR 7 CO2R 8 , R 6 is hydrogen, alkyl of 1-6 carbon atoms, aryl or aralkyl;
- R 7 is hydrogen, alkyl of 1-6 carbon atoms, aryl or aralkyl
- R 8 is hydrogen, alkyl of 1-6 carbon atoms, aryl or aralkyl; or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.
- salts can be formed from organic and inorganic acids, for example, acetic, propionic, lactic, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, phthalic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, napthalenesulfonic, benzenesulfonic, toluenesulfonic, camphorsulfonic, and similarly known acceptable acids when a compound of this invention contains a basic moiety, such as when R 5 is -CH 2 (3-pyridyl) or contains similar basic moieties.
- Salts may also be formed from organic and inorganic bases, preferably alkali metal salts, for example, sodium, lithium, or potassium, when a compound of this invention contains a carboxylate or phenolic moiety.
- Alkyl includes both straight chain as well as branched moieties.
- Halogen means bromine, chlorine, fluorine, and iodine. It is preferred that the aryl portion of the aryl or aralkyl substituent is a phenyl or naphthy; with phenyl being most preferred.
- the aryl moiety may be optionally mono-, di-, or tri- substituted with a substituent selected from the group consisting of alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, trifluoromethyl, halogen, alkoxycarbonyl of 2-7 carbon atoms, alkylamino of 1-6 carbon atoms, and dialkylamino in which each of the alkyl groups is of 1-6 carbon atoms, nitro, cyano, -CO 2 H, alkylcarbonyloxy of 2-7 carbon atoms, and alkylcarbonyl of 2-7 carbon atoms.
- the compounds of this invention may contain an asymmetric carbon atom and some of the compounds of this invention may contain one or more asymmetric centers and may thus give rise to optical isomers and diastereomers. While shown without respect to stereochemistry in Formula I, the present invention includes such optical isomers and diastereomers; as well as the racemic and resolved, enantiomerically pure R and S stereoisomers; as well as other mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof.
- the compounds of this invention may be atropisomers by virtue of possible restricted or slow rotation about the aryl-tetracyclic single bond. This restricted rotation creates additional chirality and leads to enantiomeric forms. If there is an additional chiral center in the molecule, diasteriomers exist and can be seen in the NMR and via other analytical techniques. While shown without respect to atropisomer stereochemistry in Formula I, the present invention includes such atoropisomers (enantiomers and diastereomers; as well as the racemic, resolved, pure diastereomers and mixutures of diasteomers) and pharmaceutically acceptable salts thereof.
- Preferred compounds of this invention include compounds of formula (I) in which
- a and B are each, independently, hydrogen, or bromine; C and D are OH; E is S, or O;
- X is hydrogen, halogen, alkyl of 1-6 carbon atoms, CN, alkoxy of 1-6 carbon atoms, aryloxy of 6-12 carbon atoms; arylalkoxy of 6-12 carbon atoms, arylsulfanyl, or pyridylsulfanyl;
- Y and Z are H; or a pharmaceutically acceptable salt thereof.
- A is hydrogen
- B and D are each, independently, halogen, alkyl of 1-6 carbon atoms, aryl or aralkyl of 6-12 carbon atoms, or alkoxy of 1-6 carbon atoms;
- E is S, O;
- X is hydrogen, halogen, alkyl of 1-6 carbon atoms, perfluoroalkyl of 1-6 carbon atoms, CN, alkoxy of 1-6 carbon atoms, aryloxy, arylalkoxy of 6-12 carbon atoms, arylsulfanyl, pyridylsulfanyl;
- Y and Z are H
- R 4 is H, alkyl of 1-6 carbon atoms, -CH(R 5 )W, or 5-thiazolidine-2,4-dione;
- R 5 is H, alkyl of 1-6 carbon atoms, aralkyl of 6-12 carbon atoms, aryl, -CH 2 (3-1H- indolyl) , -CH 2 CH 2 ( 1 ,3-dioxo- 1 ,3-dihydro-isoindol-2-yl), -CH 2 CH 2 ( 1 -oxo- l,3-dihydro-isoindol-2-yl), or -CH 2 (3-pyridyl);
- W is -CO 2 R 6 , -CONH 2 , -CONHOH, -5-tetrazole, or -PO 3 (R 6 ) 2 ;
- R 6 is hydrogen or alkyl of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof.
- More preferred compounds of this invention include:
- the compounds of this invention can be prepared according to the following schemes from commercially available starting materials or starting materials which can be prepared using to literature procedures. These schemes show the preparation of representative compounds of this invention.
- a benzyl halide such as benzyl bromide (PhCH 2 Br)
- This acylation is accomplished most readily using a one to five molar equivalents of a Lewis acid catalyst such as tin tetrachloride or aluminum chloride in an inert solvent such as dichloromethane, 1, 2- dichloroethane or carbon disulfide, generally at temperatures such as -78°C to room temperature.
- a Lewis acid catalyst such as tin tetrachloride or aluminum chloride
- an inert solvent such as dichloromethane, 1, 2- dichloroethane or carbon disulfide
- the reaction is best performed at - 78°C with warming to room temperature in a halocarbon solvent such as dichloromethane under an inert atmosphere such as nitrogen or argon.
- This compound can then be demethylated using boron tribromide or boron trichloride to produce the compound of formula (la: A, B, D, Y is H; C, Z is OH; E is S or O).
- the compounds of formula (la: A is H; B, D is alkyl of 1-6 carbon atoms; C is OH; Y, Z is H; E is S or O) can be prepared starting from the compound of formula (III: Q, Y, Z is H; E is S or O) and the appropriate benzoic acid chloride (IV: A is H; B, D is alkyl of 1-6 carbon atoms; C is OMe).
- the benzoic acid chloride (IV: A is H; B, D is alkyl of 1-6 carbon atoms; C is OMe) is prepared from the corresponding benzoic acid by standard procedures using reagents such as oxalyl chloride and thionyl chloride.
- the starting benzoic acid of the benzoic acid chloride (IV: A is H; B, D is alkyl of 1-6 carbon atoms; C is OMe) is commercially available or can be easily prepared by known procedures.
- the acid starting material for benzoic acid chloride (IV: A is H; B, D is is isopropyl; C is OMe) can be prepared using a modification of the method of Schuster, et al., J. Org.
- the compounds of formula (la: A, C is F; D is H; B is OH; Y, Z is H; E is S or O) can be prepared starting from the compound of formula (III: Q, Y, Z is H; E is S or O) and the appropriate benzoic acid chloride (IV: A, C is F; D is H; B is OMe).
- the benzoic acid chloride (IV: A, C is F; D is H; B is OMe) is prepared from the corresponding benzoic acid by standard procedures using reagents such as oxalyl chloride and thionyl chloride.
- the starting benzoic acid of the benzoic acid chloride (IV: A, C is F; D is H; B is OMe) can be easily prepared from the known, 4-bromo-2, 6-difluoroaniline (L. I. Kruse, et al., Biochemistry 1986, 25, 7271-7278) by reacting the latter compound with n-butyl lithium to effect deprotonation ortho to the bromine and fluorine atoms, reaction of the resultant organolithium species with carbon dioxide to install the carboxy moiety ortho to the bromine and fluorine atoms, and further reaction with n-bultyl lithium to effect lithium-bromine exchange and reaction of the final, resultant organolithium species with a proton source upon aqueous workup to provide 2, 4-difluoro, 3-methoxy benzoic acid.
- Precedence for the fluorine directed ortholithiation reaction over lithium-bromine exchange reaction is found in the following paper: F. Mongin and M. Schlosser,
- This acylation is accomplished most readily using a one to five molar equivalents of a Lewis acid catalyst such as tin tetrachloride or aluminum chloride in an inert solvent such as dichloromethane, 1, 2-dichloroethane or carbon disulfide, generally at temperatures such as -78°C to room temperature.
- a Lewis acid catalyst such as tin tetrachloride or aluminum chloride
- an inert solvent such as dichloromethane, 1, 2-dichloroethane or carbon disulfide
- Cyclization of the compounds of formula (X: A, B, C, D is H or OMe; with the A, B, C, D, combination of substituents having at least one OMe group but not more than three OMe groups) is generally best accomplished using one to ten molar equivalents of a strong Lewis acid such as a trihaloborane, most conveniently tribromoborane.
- a strong Lewis acid such as a trihaloborane, most conveniently tribromoborane.
- the reaction is best performed at -78°C with warming to room temperature in a halocarbon solvent such as dichloromethane under an inert atmosphere such as nitrogen or argon.
- the compounds of formula (la': A is H; B, D is alkyl of 1-6 carbon atoms; C is OH) can be prepared starting from the compound of formula (VIII: Q is H 2 ) and the appropriate benzoic acid chloride (IX: A is H; B, D is alkyl of 1-6 carbon atoms; C is OMe).
- the benzoic acid chloride (IX: A is H; B, D is alkyl of 1-6 carbon atoms; C is OMe). is prepared from the corresponding benzoic acid by standard procedures using reagents such as oxalyl chloride and thionyl chloride.
- the starting benzoic acid of the benzoic acid chloride (IX is H; B, D is alkyl of 1-6 carbon atoms; C is OMe) is commercially available or can be easily prepared by known procedures.
- the acid starting material for benzoic acid chloride (IX: A is H; B, D is isopropyl; C is OMe) can be prepared using a modification of the method of Schuster, et al., J. Org. Chem 1988, 53, 5819.
- the tribromophenol of formula (lb: B, D, X is Br; C is OH; E is S, O) can be methylated to produce the methyl ether of formula (lb: B, D, X is Br; C is OMe; E is S, O) by reacting the phenol moiety with a suitable methylating agent such as one or more molar equivalents of methyl iodide or dimethylsulfate employing a base such an alkali methyl carbonate or hydroxide such as potassium carbonate or sodium hydroxide in a suitable solvent such as THF, DMF or DMSO.
- a suitable methylating agent such as one or more molar equivalents of methyl iodide or dimethylsulfate
- a base such an alkali methyl carbonate or hydroxide such as potassium carbonate or sodium hydroxide
- a suitable solvent such as THF, DMF or DMSO.
- the methyl ether of formula (lb: B, D, X is Br; C is OMe; E is S, O) can be reacted with three or more molar equivalents of lower tetra-alkyltin in the presence of a palladium catalyst such as 1 to 10 mole % of bis(triphenylphosphine)palladium II chloride in a suitable solvent such as DMF, DMA or l-methyl-2-pyrrolidinone at temperatures ranging from 140°C to 200°C to provide the trialkylmethoxy derivative of formula (lb: B, D, X is alkyl of 1-6 carbon atoms; C is OMe; E is S, O).
- a palladium catalyst such as 1 to 10 mole % of bis(triphenylphosphine)palladium II chloride
- a suitable solvent such as DMF, DMA or l-methyl-2-pyrrolidinone
- This methoxy analog can be converted to the corresponding phenol analog of formula (Ic: B, D, X is alkyl of 1-6 carbon atoms; E is S, O) using standard demethylation procedures including one or more molar equivalents of boron tribromide or boron trichloride in dichloromethane at -78°C to room temperature; excess neat pyridinium hydrochloride at 190 to 280°C; hydrobromic acid in acetic acid at 0°C to 50°C; excess trimethylsilylbromide or trimethylsilyliodide in dichloromethane, carbon tetrachloride or acetonitrile at -78°C to 50°C; lithium iodide in pyridine or quinoline at temperatures from 100° to 250°C and one or more molar equivalents of ethyl, methyl or isopropyl mercaptan in the presence of one or more molar equivalents of a Lewis acid such
- the phenol of formula (lb: B, D, X is H; C is OH; E is S, O) (Scheme 2) can be conveniently iodinated to the diiodophenol of formula (lb: B, D is I; X is H; C is OH; E is S, O) using at least two molar equivalents of iodine in the presence of two or more molar equivalents of an alkali metal hydroxide such as NaOH in an alcohol solvent such as methanol at -20°C to room temperature.
- an alkali metal hydroxide such as NaOH
- the monoiodophenol (lb: B is I; X, D is H; C is OH; E is S, O) can be prepared from the phenol of formula (lb: B, D, X is H; C is OH; E is S, O) (Scheme 2) using one to 1.5 molar equivalents of iodine in the presence of at least one equivalent of an alkali metal hydroxide such as NaOH in an alcohol solvent such as methanol at -20°C to room temperature.
- an alkali metal hydroxide such as NaOH
- Either the monoiodophenol (lb: B is I; X, D is H; C is OH; E is S, O) or the diiodophenol (lb: B, D is I; X is H; C is OH; E is S, O) can be converted to the respective methyl ether derivatives of formula (lb: B is I; X, D is H; C is OMe; E is S, O) or (lb: B, D is I; X is H; C is OMe; E is S, O) by reacting the phenol moiety with a suitable methylating agent such as one or more molar equivalents of methyl iodide or dimethylsulfate employing a base such an alkali methyl carbonate or hydroxide such as potassium carbonate or sodium hydroxide in a suitable solvent such as THF, DMF or DMSO.
- a suitable methylating agent such as one or more molar equivalents of methyl iodide or dimethyl
- the monoiodo methylether derivative of formula (lb: B is I; X, D is H; C is OMe; E is S, O) or the diiodo methylether of formula (lb: B, D is I; X is H; C is OMe; E is S, O) can be reacted with one or more molar equivalents of copper (I) cyanide for the monoiodo analog or two or more molar equivalents of copper (I) cyanide for the diiodo derivative to produce the monocyanomethyl ether of formula (lb: B is CN; X, D is H; C is OMe; E is S, O) or the dicyanomethyl ether of formula (lb: B, D is CN; X is H; C is OMe; E is S, O).
- the cyanation reaction is generally performed at temperatures ranging from 100°C to 250°C employing polar aprotic solvents such as DMF, l-methyl-2-pyrrolidinone or HMPA. Quinoline or pyridine can also be used.
- the mono or dicyano methoxy analogs of formula (lb: B is CN; D is H or CN; X is H; C is OMe; E is S, O) can be converted to the corresponding mono or dicyano phenol analogs of formula (Ic: B is CN; D is H or CN; X is H; E is S, O) (Scheme 2) using standard demethylation procedures including one or more molar equivalents of boron tribromide or boron trichloride in dichloromethane at -78°C to room temperature; excess neat pyridinium hydrochloride at 190 to 280°C; hydrobromic acid in acetic acid at 0°C to 50°C; excess trimethylsilyl
- the monoiodo methylether derivative of formula (lb: B is I; X, D is H; C is OMe; E is S, O) or the diiodo methylether of formula (lb: B, D is I; X is H; C is OMe; E is S, O) (Scheme 2) can be reacted with one or more molar equivalents of copper (I) bromide for the monoiodo analog or two or more molar equivalents of copper (I) bromide for the diiodo derivative to produce the monobromo methyl ether of formula (lb: B is Br; X, D is H; C is OMe; E is S, O) or the dibromo-methyl ether of formula (lb: B, D is Br; X is H; C is OMe; E is S, O).
- the bromine/idodine exchange reaction is generally performed at temperatures ranging from 100°C to 250°C employing polar aprotic solvents such as DMF, l-methyl-2-pyrrolidinone or HMPA. Quinoline or pyridine can also be used.
- the mono or dibromo methoxy analogs of formula (lb: B is Br; D is H or Br; X is H; C is OMe; E is S, O) can be converted to the corresponding mono or dibromo phenol analogs of formula (Ic: B is Br; D is H or Br; X is H; E is S, O) (Scheme 2) using standard demethylation procedures including one or more molar equivalents of boron tribromide or boron trichloride in dichloromethane at -78°C to room temperature; excess neat pyridinium hydrochloride at 190 to 280°C; hydrobromic acid in acetic acid at 0°C to 50°C; excess trimethylsilylbromide or trimethylsilyliodide in dichloromethane, carbon tetrachloride or acetonitrile at -78°C to 50°C; lithium iodide in pyridine or quinoline at temperatures from 100° to 250
- This reaction is best known as the Suzuki reaction (N. Miyaura, T. Yanagi , A Suzuki, Synthetic Comm. 1981, 11, 513-319) and further involves the use of 0.5 to 10 mol% of a palladium catalyst such as tetakis(triphenylphosphine) palladium or a palladium (II) species such as palladium acetate or [1,1 '- bis(diphenyphosphino)ferrocene]palladium(II).
- a palladium catalyst such as tetakis(triphenylphosphine) palladium or a palladium (II) species such as palladium acetate or [1,1 '- bis(diphenyphosphino)ferrocene]palladium(II).
- a palladium catalyst such as tetakis(triphenylphosphine) palladium or a palladium (II) species such as palladium acetate or
- the reaction can be run in a variety of solvents including benzene, THF, dioxane, DME or DMF.
- solvents such as THF and benzene
- water or methanol can be used as a colvent.
- the reaction is generally run at temperatures ranging from room temperature to 120°C.
- the mono or dibromo methoxy analogs of formula (lb: B is Br; D is H or Br; X is H; C is OMe; E is S, O) and the mono and diphenyl methoxy analogs of formula (lb: B is Ph; D is H or Ph; X is H; C is OMe; E is S, O) can be converted to the corresponding mono or dibromo phenol analogs of formula (Ic: B is Br; D is H or Br; X is H; E is S, O) or the mono and diphenyl phenol analogs of formula (lb: B is Ph; D is H or Ph; X is H; C is OH; E is S, O) (Scheme 2) using standard demethylation procedures including one or more molar equivalents of boron tribromide or boron trichloride in dichloromethane at -78°C to room temperature; excess neat pyridinium hydrochloride at 190 to 280°C; hydrobro
- the acylating agent is generally a alkyl of 1-6 carbon atoms or aryl carboxy lie acid anhydride or a alkyl of 1-6 carbon atoms or aryl carboxylic acid chloride.
- the reaction is run under standard conditions, for example, the use of pyridine as solvent with or without a co-solvent such as dichloromethane at 0°C to room temperature.
- the acylated phenols of formula (Id: B, C, D is H or OCOR; with the B, C, D combination having at least one OCOR group; R is alkyl of 1-6 carbon atoms, aryl; E is S, O) can then be brominated in the 6-position of the benzo[b]naphtho[2,3-d]thiophene or benzo[b]naphtho[2,3-d]furan ring to form the acylated bromophenols of formula (le: B, C, D is H or OCOR; with the B, C, D combination having at least one OCOR group; R is alkyl of 1-6 carbon atoms, aryl; X is Br; E is S, O) (Scheme 3).
- This bromination reaction is generally done using 1 to 1.3 molar equivalents of molecular bromine in an inert solvent such as dichloromethane or carbon tetrachloride at temperatures ranging from
- the phenols of formula (Id: B, D is alkyl of 1-6 carbon atoms, C is OH; E is S, O) can then be brominated in the 6-position of the benzo[b]naphtho[2,3-d]thiophene or benzo[b]naphtho[2,3-d]furan ring to form the bromophenols of formula (le: B, D is alkyl of 1-6 carbon atoms, C is OH; X is Br; E is S, O) (Scheme 3).
- This bromination reaction is generally done using 1 to 1.3 molar equivalents of molecular bromine in an inert solvent such as dichloromethane or carbon tetrachloride at temperatures ranging from -78 °C to room temperature.
- the acyl group can then be removed from the acylated bromophenols of formula (le: B, C, D is H or OCOR; with the B, C, D combination having at least one OCOR group; R is alkyl of 1-6 carbon atoms, aryl; X is Br; E is S, O) to provide the bromophenols of formula (le: B, C, D is H or OH; with the B, C, D combination having at least one OH group; X is Br; E is S, O) (Scheme 3) using standard conditions.
- These conditions include aqueous base in which one or more molar equivalents of alkali metal hydroxide such as sodium hydroxide is used in water with a co-solvent such as THF, dioxane or a lower alcohol such as methanol or mixtures of THF and a lower alcohol at temperatures ranging from 0°C to 40°C.
- acid conditions may also be employed in which the compound is reacted with one or more molar equivalents of a mineral acid such as HC1 or sulfuric acid in water with or without a co-solvent such as THF at temperatures ranging from room temperature to 80°C.
- the acylated phenols of formula (Id: B, C, D is H or OCOR; with the B, C, D combination having at least one OCOR group; R is alkyl of 1-6 carbon atoms, aryl; E is S, O) can be nitrated to provide the nitro compounds of formula (le: B, C, D is H or OCOR; with the B, C, D combination having at least one OCOR group; R is alkyl of 1-6 carbon atoms, aryl; X is NO 2 ; E is S, O) (Scheme 3).
- Dilute nitric acid at temperatures ranging from 0°C to room temperature is suitable to effect this transformation.
- the nitro compounds of formula (le: B, C, D is H or OCOR; with the B, C, D combination having at least one OCOR group; R is alkyl of 1-6 carbon atoms, aryl; X is NO 2 ; E is S, O) can be further reduced to the primary amine of formula (le: B, C, D is H or OCOR; with the B, C, D combination having at least one OCOR group; R is alkyl of 1-6 carbon atoms, aryl; X is NH 2 ; E is S, O) using a suitable reducing agent such as catalytic hydrogenation with a palladium or platinum catalyst, tin dichloride in aqueous HC1 or in ethyl acetate.
- a suitable reducing agent such as catalytic hydrogenation with a palladium or platinum catalyst, tin dichloride in aqueous HC1 or in ethyl acetate.
- the acyl group of the compounds of formula (le: B, C, D is H or OCOR; with the B, C, D combination having at least one OCOR group; R is alkyl of 1-6 carbon atoms, aryl; X is NO 2 or NH 2 ; E is S, O) can be removed by using standard conditions to provide the phenols of formula (le: B, C, D is H or OH; with the B, C, D combination having at least one OH group; R is alkyl of 1-6 carbon atoms, aryl; X is NO 2 or NH 2 ; E is S, O).
- the acylated bromophenols of formula (le: B, C, D is H or OCOR; with the B, C, D combination having at least one OCOR group; R is alkyl of 1-6 carbon atoms, aryl; X is Br; E is S, O) (Scheme 3) can be converted to the acylated cyanophenols of formula (le: B, C, D is H or OCOR; with the B, C, D combination having at least one OCOR group; R is alkyl of 1-6 carbon atoms, aryl; X is CN; E is S, O) by reaction with one or more molar equivalents of copper (I) cyanide.
- the cyanation reaction is generally performed at temperatures ranging from 100°C to 250°C employing polar aprotic solvents such as DMF, l-methyl-2-pyrrolidinone or HMPA. Quinoline or pyridine can also be used.
- polar aprotic solvents such as DMF, l-methyl-2-pyrrolidinone or HMPA.
- Quinoline or pyridine can also be used.
- the acyl group can also be removed from the isolated acylated cyanophenols of formula (le: B, C, D is H or OCOR; with the B, C, D combination having at least one OCOR group; R is alkyl of 1-6 carbon atoms, aryl; X is CN; E is S, O) to provide the cyanophenols of formula (le: B, C, D is H or OH; with the B, C, D combination having at least one OH group; X is CN; E is S, O) by using standard conditions.
- These conditions include aqueous base in which one or more molar equivalents of alkali metal hydroxide such as sodium hydroxide is used in water with a co-solvent such as THF, dioxane or a lower alcohol such as methanol or mixtures of THF and a lower alcohol at temperatures ranging from 0°C to 40°C.
- acid conditions may also be employed in which the compound is reacted with one or more molar equivalents of a mineral acid such as HC1 or sulfuric acid in water with or without a co-solvent such as THF at temperatures ranging from room temperature to 80°C.
- the compounds of formula (Id: B, C, D is H or OH; with the B, C, D combination having at least one OH group; E is S, O) (Scheme 3) can be sulfonylated on the phenolic oxygen using one or more molar equivalents of suitable sulfonylating agent to provide the sulfonic acid esters of formula (Id: B, C, D is H or OSO 2 R; with the B, C, D combination having at least one OSO 2 R group; R is alkyl of 1-6 carbon atoms, aryl; E is S, O).
- the sulfonylating agent is generally a alkyl of 1-6 carbon atoms or aryl sulfonic acid anhydride or a alkyl of 1-6 carbon atoms or aryl sulfonic acid chloride.
- the reaction is run under standard conditions such as using pyridine as solvent with or without a co-solvent such as dichloromethane at 0°C to room temperature.
- the sulfonic acid esters of formula (Id: B, C, D is H or OSO 2 R; with the B, C, D combination having at least one OSO 2 R group; R is alkyl of 1-6 carbon atoms, aryl; E is S, O) can be treated with a chlorinating agent to effect chlorination at the 6- position of the benzo[b]naphtho[2,3-d]thiophene or benzo[b]naphtho[2,3-d]furan ring to afford the chloro-sulfonic acid esters of formula (le: B, C, D is H or OSO 2 R; with the B, C, D combination having at least one OSO 2 R group; R is alkyl of 1-6 carbon atoms, aryl; X is Cl; E is S, O).
- Suitable chlorinating agents include one or more molar equivalents of sulfuryl chloride, chlorine gas or N-chlorosuccinimide in suitable halocarbon solvents such as dichloromethane or chloroform at temperatures ranging from -78°C to 40 °C.
- the sulfonic ester group can then be removed from the chloro-sulfonic acid esters of formula (le: B, C, D is H or OSO 2 R; with the B, C, D combination having at least one OSO 2 R group; R is alkyl of 1-6 carbon atoms, aryl; X is Cl; E is S, O) to provide the chlorophenols of formula (le: B, C, D is H or OH; with the B, C, D combination having at least one OH group; X is Cl; E is S, O) (Scheme 3) using standard conditions.
- These conditions include aqueous base in which one or more molar equivalents of alkali metal hydroxide such as sodium hydroxide is used in water with a co-solvent such as THF, dioxane or a lower alcohol such as methanol or mixtures of THF and a lower alcohol at temperatures ranging from room temperature to l l0°C.
- a co-solvent such as THF, dioxane or a lower alcohol
- methanol or mixtures of THF and a lower alcohol at temperatures ranging from room temperature to l l0°C.
- the sulfonic acid esters of formula (Id: B, C, D is H or OSO 2 R; with the B, C, D combination having at least one OSO 2 R group; R is alkyl of 1-6 carbon atoms, aryl; E is S, O) can also be treated with iodinating reagents to effect iodination at the 6- position of the benzo[b]naphtho[2,3-d]thiophene or benzo[b]naphtho[2,3-d]furan ring to afford the iodo-sulfonic acid esters of formula (le: B, C, D is H or OSO 2 R; with the B, C, D combination having at least one OSO 2 R group; R is alkyl of 1-6 carbon atoms, aryl; X is I; E is S, O).
- a suitable iodinating reagent includes a mixture of 0.7 or more molar equivalents of molecular iodine and 0.25 or more molar equivalents of iodic acid in a mixture of THF and 80% aqueous acetic acid with a small amount of concentrated sulfuric acid at temperatures ranging from room temperature to 80°C.
- the sulfonic ester group can then be removed from the iodo-sulfonic acid esters of formula (le: B, C, D is H or OSO 2 R; with the B, C, D combination having at least one OSO 2 R group; R is alkyl of 1-6 carbon atoms, aryl; X is I; E is S, O) to provide the iodophenols of formula (le: B, C, D is H or OH; with the B, C, D combination having at least one OH group; X is I; E is S, O) (Scheme 3) using standard conditions.
- These conditions include aqueous base in which one or more molar equivalents of alkali metal hydroxide such as sodium hydroxide is used in water with a co-solvent such as THF, dioxane or a lower alcohol such as methanol or mixtures of THF and a lower alcohol at temperatures ranging from room temperature to 110°C.
- a co-solvent such as THF, dioxane or a lower alcohol
- THF methanol or mixtures of THF and a lower alcohol
- the reagent and conditions to effect this exchange include reacting (If) under anhydrous conditions with one to ten molar molar equivalents of a sodium perfluorocarboxylate (RCO 2 Na: R is perfluoroalkyl) and one to five molar molar equivalents of copper (I) iodide in a high boiling inert solvent such as DMF, DMA or l-methyl-2-pyrrolidinone at temperatures ranging from 140°C to 200°C.
- a sodium perfluorocarboxylate RCO 2 Na: R is perfluoroalkyl
- copper (I) iodide in a high boiling inert solvent such as DMF, DMA or l-methyl-2-pyrrolidinone at temperatures ranging from 140°C to 200°C.
- the compound of formula (Ig: C, D is H or OSO 2 R; C, D cannot both be H; R is alkyl of 1-6 carbon atoms, aryl; X is perfluoroalkyl of 1-6 carbon atoms; E is S, O) can be prepared from the compound of formula (If: C, D is H or OSO 2 R; C, D cannot both be H; R is alkyl of 1-6 carbon atoms, aryl; E is S, O) by reacting the former with one to ten molar molar equivalents of a perfluoroalkyl iodide and one to five molar molar equivalents of activated Cu° in a high boiling inert solvent such as DMF, DMA or l-methyl-2-pyrrolidinone at temperatures ranging from 140°C to 200°C.
- a high boiling inert solvent such as DMF, DMA or l-methyl-2-pyrrolidinone
- the compound of formula (If: C, D is H or OSO 2 R; C, D cannot both be H; R is alkyl of 1-6 carbon atoms, aryl; E is S, O) can be reacted with 0.5 to two molar equivalents of bis(trifluoromethylmercury) and two to four molar equivalents of activated Cu° in a high boiling inert solvent such as DMF, DMA or l-methyl-2-pyrrolidinone at temperatures ranging from 140°C to 200°C to produce the compound of (Ig: C, D is H or OSO 2 R; C, D cannot both be H; R is alkyl of 1-6 carbon atoms, aryl; X is CF 3 ; E is S, O).
- a high boiling inert solvent such as DMF, DMA or l-methyl-2-pyrrolidinone
- 6- Alkyl of 1-6 carbon atoms derivatives of the compound of formula (Ig: C, D is H or OSO 2 R; C, D cannot both be H; R is alkyl of 1-6 carbon atoms, aryl; X is alkyl of 1-6 carbon atoms; E is S, O) (Scheme 4) can be prepared by reaction of (If: C, D is H or OSO 2 R; C, D cannot both be H; R is alkyl of 1-6 carbon atoms, aryl; E is S, O) with three or more molar equivalents of lower tetra-alkyltin in the presence of a palladium catalyst such as 1 to 10 mole % of bis(triphenylphosphine)palladium II chloride in a suitable solvent such as DMF, DMA or l-methyl-2-pyrrolidinone at temperatures ranging from 140°C to 200°C.
- a palladium catalyst such as 1 to 10 mole % of bis(triphenyl
- the sulfonic ester group can then be removed from the sulfonic acid esters of formula (Ig: C, D is H or OSO 2 R; C, D cannot both be H; R is alkyl of 1-6 carbon atoms, aryl; X is alkyl of 1-6 carbon atoms or perfluoroalkyl of 1-6 carbon atoms; E is S, O) to provide the phenols of formula (Ig: C, D is H or OH; C, D cannot both be H; X is alkyl of 1-6 carbon atoms or perfluoroalkyl of 1-6 carbon atoms; E is S, O) using standard conditions.
- These conditions include aqueous base in which one or more molar equivalents of alkali metal hydroxide such as sodium hydroxide is used in water with a co-solvent such as THF, dioxane or a lower alcohol such as methanol or mixtures of THF and a lower alcohol at temperatures ranging from room temperature to l lO°C.
- a co-solvent such as THF, dioxane or a lower alcohol
- methanol or mixtures of THF and a lower alcohol at temperatures ranging from room temperature to l lO°C.
- 6-Alkoxy derivatives of the compound of formula (Ig: C, D is H, OH; C, D cannot both be H; X is alkoxy of 1-6 carbon atoms; E is S, O) can be prepared by reaction of (If: C, D is H or OSO 2 R; C, D cannot both be H; R is alkyl of 1-6 carbon atoms, aryl; E is S, O) with three or more molar equivalents of lower alkali metal alkoxide in the presence of a copper (I) or copper (II) catalyst such as 1 to 10 mole % copper (II) chloride in a suitable solvent such as DMF, DMA or l-methyl-2- pyrrolidinone at temperatures ranging from 80°C to 180°C. Under the reaction conditions, the sulfonic acid group of (If: C, D is H or OSO 2 R; C, D cannot both be H; R is alkyl of 1-6 carbon atoms, aryl; E is S, O) is
- X is alkylsulfanyl of 1-6 carbon atoms, arylsulfanyl, pyridylsulfanyl, 2-N,N-dimethylaminoethylsulfanyl;
- E is S, O
- C, D is H or OSO 2 R; C, D cannot both be H;
- R is alkyl of 1-6 carbon atoms, aryl; E is S, O) with one or more molar equivalents of the appropriate alkyl of 1-6 carbon atomsthiol, arylthiol, thiopyridine or 2-N,N-dimethylaminoethyl- mercaptan, one or more molar equivalents of an alkali metal hydroxide such as sodium hydroxide, one or more molar equivalents of a copper (I) or copper (
- the dibromo-bisphenols of formula (Ii: A is OH; B, D is Br; X is H; E is S, O) can be further brominated in the 6-position of the benzo[b]naphtho[2,3-d]thiophene ring to form the bisphenols of formula (Ii: A is OH; B, D, X is Br; E is S, O).
- This bromination reaction is generally done using 1 to 1.3 molar equivalents of molecular bromine in an inert solvent such as dichloromethane or carbon tetrachloride at temperatures ranging from -78 °C to room temperature.
- the bisphenols of formula (Ij: C, D is OH;
- X is halogen, alkyl of 1-6 carbon atoms, CN, perfluoroalkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy, nitro, alkylsulfanyl of 1-6 carbon atoms, arylsulfanyl, pyridylsulfanyl, 2-N,N-dimethylaminoethylsulfanyl;
- E is S, O
- A is H;
- B is Br;
- C, D is OH;
- X is halogen, alkyl of 1-6 carbon atoms, CN, perfluoroalkyl of 1- 6 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy, nitro, alkylsulfanyl of 1-6 carbon atoms, aryl
- D is OH;
- X is halogen, alkyl of 1-6 carbon atoms, CN, perfluoroalkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy, nitro, alkylsulfanyl of 1-6 carbon atoms, arylsulfanyl, pyridylsulfanyl, 2-N,N-dimethylamino-ethylsulfanyl; E is S, O) can be further alkylated with a alkyl of 1-6 carbon atoms halide to provide the dialkylated product of formula (Ik: A is H; B is Br; C is benzyloxy, D is alkoxy of 1-6 carbon atoms; X is halogen, alkyl of 1-6 carbon atoms, CN, perfluoroalkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy, nitro, alkyls
- E is S, O
- This product may be contaminated with small amounts ( ⁇ 10%) of the regioisomer of formula (Im: C is OCH 2 CO 2 CH 3 ; Y is OH; Z is H; E is S).
- the regioisomers can be separated by conventional means.
- the bisphenols of formula (II: Y, C is OH; Z is H; E is S) or (Z, C is OH; Y is H; E is S or O) can be diaklylated with two or more molar equivalents of an alkyl haloacetate of formula (X 2 CH 2 CO 2 R 6 where X 2 is Cl, Br or I and R 6 is alkyl of 1-6 carbon atoms) and with two or more molar equivalents of an alkali metal carbonate such as potassium carbonate in a polar aprotic solvent such as DMF to afford the dialkylated product of formula (Im: Y, C is OCH 2 CO 2 R 6 ; Z is H; E is S; R 6 is alkyl of 1-6 carbon atoms) or (Z, C is OCH 2 CO 2 R 6 ; Y is H; E is S or O; R 6 is alkyl of 1-6 carbon atoms).
- the monoesters of formula (Im: Y is OCH 2 CO 2 CH 3 ; C is OH; Z is H; E is S) as well as the diesters of formula (Im: Y, C is OCH 2 CO 2 R 6 ; Z is H; E is S; E is S) or (Z, C is OCH 2 CO 2 R 6 ; Y is H; E is S or O) can be transformed into their carboxylic acid analogs using standard conditions to afford the moncarboxylic acids of formula (Im: Y is OCH 2 CO 2 H; C is OH; Z is H; E is S) and the dicarboxylic acids of formula (Im: Y, C is OCH 2 CO 2 H; Z is H; E is S) or (Z, C is OCH 2 CO 2 H; Y is H; E is S or O).
- the conditions to effect these transformations include aqueous base in which one or more molar equivalents of alkali metal hydroxide such as sodium hydroxide is used in water with a co-solvent such as THF, dioxane or a lower alcohol such as methanol or mixtures of THF and a lower alcohol at temperatures ranging from 0°C to 40°C.
- a co-solvent such as THF, dioxane or a lower alcohol
- methanol or mixtures of THF and a lower alcohol at temperatures ranging from 0°C to 40°C.
- the bisphenols of formula (In: A, B is H or Br; C, D is OH; X is halogen, alkyl of 1-6 carbon atoms, CN, perfluoroalkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy, nitro, alkylsulfanyl of 1-6 carbon atoms, arylsulfanyl, pyridylsulfanyl, 2-N,N-dimethylaminoethylsulfanyl; E is S, O) can be diaklylated with two or more molar equivalents of an alkyl haloacetate of formula (X 2 CHR 6 CO 2 R 6 where X 2 is Cl, Br or I and R 6 is alkyl of 1-6 carbon atoms, R 6' is H) and with two or more molar equivalents of an alkali metal carbonate such as potassium carbonate in a polar aprotic solvent such as DMF to afford the
- the other co-reagents necessary to effect the Mitsunobu Reaction include one or more molar equivalents of a alkyl of 1-6 carbon atoms azodicarboxylate diester such as diethyl azodicarboxylate or diisopropyl azodicarboxylate and one or more molar equivalents of triarylphosphine such as triphenylphosphine in a suitable solvent such as diethyl ether, THF, benzene or toluene at temperatures ranging from -20°C to 120°C.
- X is halogen, alkyl of 1-6 carbon atoms, CN, perfluoroalkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy, nitro, alkylsulfanyl of 1-6 carbon atoms, arylsulfanyl, pyridylsulfanyl, 2-N,N-dimethylaminoethylsulfanyl; R 6 , R 6 is alkyl of 1-6 carbon atoms, aralkyl, aryl; E is S, O) as well as the diesters of formula (Io: A, B is H or Br; C is OCHR 6 CO 2 R 6 , X is halogen, alkyl of 1-6 carbon atoms, CN, perfluoroalkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy, nitro, alkylsulfanyl of 1-6
- the conditions to effect these transformations include aqueous base in which one or more molar equivalents of alkali metal hydroxide such as sodium hydroxide is used in water with a co-solvent such as THF, dioxane or a lower alcohol such as methanol or mixtures of THF and a lower alcohol at temperatures ranging from 0°C to 40°C.
- a co-solvent such as THF, dioxane or a lower alcohol
- methanol or mixtures of THF and a lower alcohol at temperatures ranging from 0°C to 40°C.
- A is H or OH
- B, D is H, halogen, CN, alkyl of 1-6 carbon atoms, aryl, aralkyl, alkoxy of 1-6 carbon atoms, nitro
- Y, Z is H or OCH 2 CO 2 R 6 , but Y and Z are not concurrently OCH 2 CO 2 R 6
- the other co-reagents necessary to effect the Mitsunobu Reaction include one or more molar equivalents of a alkyl of 1-6 carbon atoms azodicarboxylate diester such as diethyl azodicarboxylate or diisopropyl azodicarboxylate and one or more molar equivalents of triarylphosphine such as triphenylphosphine in a suitable solvent such as diethyl ether, THF, benzene or toluene at temperatures ranging from -20°C to 120°C.
- the 2-hydroxy carboxylic acid ester of formula CH(OH)(R 5 )CO 2 R 6 (R 5 is H, alkyl of 1-6 carbon atoms, aralkyl, aryl, CH 2 (lH-imidazol-4-yl), CH 2 (3-1H- indolyl), CH 2 CH 2 ( 1 ,3-dioxo- 1 ,3-dihydro-isoindol-2-yl), CH 2 CH 2 ( 1 -oxo- 1 ,3-dihydro- isoindol-2-yl), CH 2 (3-pyridyl), CH 2 CO 2 R 6 , R 6 is alkyl of 1-6 carbon atoms) are commercially available or can be prepared from commercially available carboxylic acid precursors under standard esterification conditions.
- (S)-(+)-2-Hydroxy-l-oxo-3- dihydro-2-isoindolinebutyric acid, methyl ester can be prepared from (S)-(+)-2- hydroxy-l,3-dioxo-2-isoindolinebutyric acid, methyl ester via sequential treatment with 1) sodium borohydride in THF- water; 2) trifluoroacetic acid / chloroform; 3) triethylsilane / trifluoroacetic acid and 4) aqueous sodium bicarbonate.
- 3-(Pyridin-3-yl)-phenyllactic acid, ethyl ester can be prepared according to the two step procedure of B.A. Lefker, W.A. Hada, P.J. McGarry Tetrahedron Lett. 1994, 35, 5205-5208, from commericially available 3-pyridinecarboxaldehyde and ethyl chloroacetate.
- a strong base such as lithium diisopropyl amide
- suitable solvent such as THF
- X is H, halogen, alkyl of 1-6 carbon atoms, CN, perfluoroalkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy, nitro, alkylsulfanyl of 1-6 carbon atoms, arylsulfanyl, pyridylsulfanyl, 2-N,N-dimethylamino-ethylsulfanyl; W is CO 2 R 6 ; R 5 is H, alkyl of 1- 6 carbon atoms, aralkyl, aryl, CH 2 (lH-imidazol-4-yl), CH 2 (3-lH-indolyl), CH 2 CH 2 ( 1 ,3-d
- the conditions to effect these transformations include aqueous base in which one or more molar equivalents of alkali metal hydroxide such as sodium hydroxide is used in water with a co-solvent such as THF, dioxane or a lower alcohol such as methanol or mixtures of THF and a lower alcohol at temperatures ranging from 0°C to 40°C.
- a co-solvent such as THF, dioxane or a lower alcohol such as methanol or mixtures of THF and a lower alcohol at temperatures ranging from 0°C to 40°C.
- acid conditions may also be employed in which the above mentioned carboxylic acid ester of formula (Iq) is reacted with one or more molar equivalents of a mineral acid such as HC1 or sulfuric acid in water with or without a co-solvent such as THF at temperatures ranging from room temperature to 80°C.
- ester to acid transformation leading to (Iq) include reacting the carboxylic acid ester of formula (Iq) with one or more molar equivalents of boron tribromide or boron trichloride in dichloromethane at -78°C to room temperature; one or more molar equivalents hydrobromic acid in acetic acid at 0°C to 50°C; one or more molar equivalents trimethylsilylbromide or trimethylsilyliodide in dichloromethane, carbon tetrachloride or acetonitrile at -78°C to 50°C; one or more molar equivalents lithium iodide in pyridine or quinoline at temperatures from 100° to 250°C.
- A is H;
- B, D is H, halogen, CN, alkyl of 1-6 carbon atoms, aryl, aralkyl, alkoxy of 1-6 carbon atoms, nitro;
- Y, Z is H or OCH 2 CO 2 R 6 , but Y and Z are not concurrently OCH 2 C 2 R 6 ;
- X is H, halogen, alkyl of 1-6 carbon atoms, CN, perfluoroalkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy, nitro, alkylsulfanyl of 1-6 carbon atoms, arylsulfanyl, pyridylsulfanyl, 2-N,N-dimethylamino-ethylsulfanyl;
- R 6 is alkyl of 1-6 carbon atoms;
- E is S, O) can be alkylated with one or more molar equivalents of diethyl tri
- A is H
- B is H, halogen, CN, alkyl of 1-6 carbon atoms, aryl, aralkyl, alkoxy of 1-6 carbon atoms, nitro
- Y is H or OCH 2 CO 2 R 6 , but Y and Z are not concurrently OCH 2 CO 2 R 6
- X is H, halogen, alkyl of 1-6 carbon atoms, CN, perfluoroalkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy, nitro, alkylsulfanyl of 1-6 carbon atoms, arylsulfanyl, pyridyl- sul
- A is H or OH
- B, D is H, halogen, CN, alkyl of 1-6 carbon atoms, aryl, aralkyl, alkoxy of 1-6 carbon atoms, nitro
- Y, Z is H or OCH 2 CO 2 R 6 , but Y and Z are not concurrently OCH 2 CO 2 R 6
- the other co-reagents necessary to effect the Mitsunobu Reaction include one or more molar equivalents of a alkyl of 1-6 carbon atoms azodicarboxylate diester such as diethyl azodicarboxylate or diisopropyl azodicarboxylate and one or more molar equivalents of triarylphosphine such as triphenylphosphine in a suitable solvent such as diethyl ether, THF, benzene or toluene at temperatures ranging from -20°C to 120°C.
- azodicarboxylate diester such as diethyl azodicarboxylate or diisopropyl azodicarboxylate
- triarylphosphine such as triphenylphosphine in a suitable solvent such as diethyl ether, THF, benzene or toluene at temperatures ranging from -20°C to 120°C.
- the 2-hydroxy phosphonic acid diester of formula CH(OH)(R 5 )PO 3 R 6 (R 5 is H, alkyl of 1-6 carbon atoms, aralkyl, aryl, R 6 is alkyl of 1-6 carbon atoms) can be prepared by reacting a dialklylphosphonate of formula HP(O)(OR 6 ) 2 (R 6 is alkyl of 1-6 carbon atoms) with an aldehyde of formula R 5 CHO (R 5 is alkyl of 1-6 carbon atoms, aryl, aralkyl) under standard conditions.
- A is H or OH
- B is H, halogen, CN, alkyl of 1-6 carbon atoms, aryl, aralkyl, alkoxy of 1-6 carbon atoms, nitro
- Y, Z is H or OCH 2 CO 2 R 6 , but Y and Z are not concurrently OCH 2 CO 2 R 6
- X is H, halogen, alkyl of 1-6 carbon atoms, CN, perfluoroalkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy, nitro, alkylsulfanyl of 1-6 carbon atoms, arylsulfanyl, pyridylsulfanyl, 2-N,N-dimethylamino-ethylsulfanyl;
- W is PO 3 (R 6 ) 2
- R 5 is H, alkyl of 1-6 carbon atoms, aralkyl,
- A is H or OH
- Y Z is H
- X is H, halogen, alkyl of 1-6 carbon atoms, CN, perfluoroalkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy, nitro, alkylsulfanyl of 1-6 carbon atoms, arylsulfanyl, pyridylsulfanyl, 2-N,N-dimethylamino-ethylsulfanyl;
- W is CO 2 R 6 ;
- R 5 is H, alkyl of 1- 6 carbon atoms, aralkyl, aryl, CH 2 (lH-imidazol-4-yl), CH 2 (3-lH-indolyl), CH 2 CH 2 (
- This transformation can be accomplished using standard methods to effect carboxylic acid to carboxylic acid amide transformations. These methods include converting the acid to an activated acid and reacting with one or more molar equivalents of the desired amine. Amines in this category include ammonia in the form of ammonium hydroxide, hydroxyl amine and 2-aminopropionitrile. Methods to activate the carboxylic acid include reacting said acid with one or more molar equivalents of oxalyl chloride or thionyl chloride to afford the carboxylic acid chloride in a suitable solvent such as dichloromethane, chloroform or diethyl ether.
- This reaction is often catalyzed by adding small amounts (0.01 to 0.1 molar equivalents) of dimethylformamide.
- Other methods to activate the carboxylic acid include reacting said acid with one or more molar equivalents dicyclohexylcarbodiimide with or without one or more molar equivalents of hydroxybenzotriazole in a suitable solvent such as dichloromethane or dimethylformamide at temperatures ranging from 0°C to 60°C.
- A is H or OH
- Y Z is H
- X is H, halogen, alkyl of 1-6 carbon atoms, CN, perfluoroalkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy, nitro, alkylsulfanyl of 1-6 carbon atoms, arylsulfanyl, pyridylsulfanyl, 2-N,N- dimethylamino-ethylsulfanyl;
- W is CONH 2 ;
- R 5 is H, alkyl of 1-6 carbon atoms, aralkyl, aryl, CH 2 (lH-imidazol-4-yl), CH 2 (3-lH-indolyl), CH
- One set of conditions to effect this transformation include reacting the said primary carboxylic acid amide with one or more molar equivalents of trifluoroacetic anhydride and two or more molar equivalents of pyridine in a suitable solvent such as dioxane at temperatures ranging from 60°C to 120°C.
- A is H or OH
- Y Z is H
- X is H, halogen, alkyl of 1-6 carbon atoms, CN, perfluoroalkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy, nitro, alkylsulfanyl of 1-6 carbon atoms, arylsulfanyl, pyridylsulfanyl, 2-N,N-dimethylamino-ethylsulfanyl;
- W is CN;
- R 5 is H, alkyl of 1-6 carbon atoms, aralkyl, aryl, CH 2 (lH-imidazol-4-yl), CH 2 (3-1 H-indolyl), CH 2 CH 2 (1,3-
- the nitrile fuction can be reacted with one or more molar equivalents of ammonium azide in a suitable solvent such as dimethylformamide at temperatures ranging from 60°C to 160°C.
- X is H, halogen, alkyl of 1-6 carbon atoms, CN, perfluoroalkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy, nitro, alkylsulfanyl of 1-6 carbon atoms, arylsulfanyl, pyridylsulfanyl, 2-N,N-dimethylamino-ethylsulfanyl; W is CO 2 R 6 ; R 5 is H, alkyl of 1- 6 carbon
- the other co-reagents necessary to effect the Mitsunobu Reaction include one or more molar equivalents of a alkyl of 1-6 carbon atoms azodicarboxylate diester such as diethyl azodicarboxylate or diisopropyl azodicarboxylate and one or more molar equivalents of triarylphosphine such as triphenylphosphine in a suitable solvent such as diethyl ether, THF, benzene or toluene at temperatures ranging from -20°C to 120°C at temperatures ranging from -20°C to 120°C.
- the 2-hydroxy carboxylic acid ester of formula CH(OH)(R la )CO 2 R 1 (R 1 , R la s alkyl of 1-6 carbon atoms, aralkyl, aryl) are commercially available or can be prepared from commercially available carboxylic acid precursors under standard esterification conditions .
- R 1 is alkyl of 1-6 carbon atoms, aralkyl, aryl
- R la is H or alkyl of 1-6 carbon atoms, aralkyl, aryl
- E is S, O
- the conditions to effect these transformations include aqueous base in which one or more molar equivalents of alkali metal hydroxide such as sodium hydroxide is used in water with a co-solvent such as THF, dioxane or a lower alcohol such as methanol or mixtures of THF and a lower alcohol at temperatures ranging from 0°C to 40°C.
- a co-solvent such as THF, dioxane or a lower alcohol
- methanol or mixtures of THF and a lower alcohol at temperatures ranging from 0°C to 40°C.
- R 4 is (R, S)-5- thiazolidine-2,4-dione
- B, D is H, halogen, CN, alkyl of 1-6 carbon atoms, aryl, aralkyl, alkoxy of 1-6 carbon atoms, nitro
- the phenols of formula (It: B, D is H, halogen, CN, alkyl of 1-6 carbon atoms, aryl, aralkyl, alkoxy of 1-6 carbon atoms, nitro;
- X is halogen, alkyl of 1-6 carbon atoms, CN, perfluoroalkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy, nitro, alkylsulfanyl of 1-6 carbon atoms, arylsulfanyl, pyridyl- sulfanyl, 2-N,N-dimethylamino-ethylsulfanyl;
- E is S, O) can be reacted with one or more molar equivalents of tetrazole and di-tert-butyl N,N-diethylphosporamidate in THF at room temperature followed by addition of one or more molar equivalents of meta-chlorobenzoic
- R 4 is P(O)(OtBu) 2
- B D is H, halogen, CN, alkyl of 1-6 carbon atoms, aryl, aralkyl, alkoxy of 1-6 carbon atoms, nitro
- R 4 is P(O)(OH) 2 ;
- B, D is H, halogen, CN, alkyl of 1-6 carbon atoms, aryl, aralkyl, nitro;
- the phenols of formula (It: B, D is H, halogen, CN, alkyl of 1-6 carbon atoms, aryl, aralkyl, alkoxy of 1-6 carbon atoms, nitro;
- X is halogen, alkyl of 1-6 carbon atoms, CN, perfluoroalkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy, nitro, alkylsulfanyl of 1-6 carbon atoms, arylsulfanyl, pyridylsulfanyl, 2-N,N- dimethylamino-ethylsulfanyl;
- E is S, O)
- R 4 is C(CH 3 ) 2 CO 2 H
- B, D is H, halogen, CN, alkyl of 1-6 carbon atoms, aryl, aralkyl, alkoxy of 1-6 carbon atoms, nitro;
- the phenols of formula (It: B, D is H, halogen, CN, alkyl of 1-6 carbon atoms, aryl, aralkyl, alkoxy of 1-6 carbon atoms, nitro;
- X is halogen, alkyl of 1-6 carbon atoms, CN, perfluoroalkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy, nitro, alkylsulfanyl of 1-6 carbon atoms, arylsulfanyl, pyridylsulfanyl, 2-N,N- dimethylamino-ethylsulfanyl;
- E is S, O
- R 4 is CH 2 CH 2 CO 2 H
- B, D is H, halogen, CN, alkyl of 1-6 carbon atoms, aryl, aralkyl, alkoxy of 1-6 carbon atoms, nitro
- X is
- the phenols of formula (It: B, D is H, halogen, CN, alkyl of 1-6 carbon atoms, aryl, aralkyl, alkoxy of 1-6 carbon atoms, nitro;
- X is halogen, alkyl of 1-6 carbon atoms, CN, perfluoroalkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy, nitro, alkylsulfanyl of 1-6 carbon atoms, arylsulfanyl, pyridylsulfanyl, 2- N,N-dimethylamino-ethylsulfanyl;
- E is S, O) can be reacted with a 3-hydroxy carboxylic acid ester of formula CH(OH)(R 7 )CH 2 CO 2 R 6 (R 7 is H or alkyl of 1-6 carbon atoms; R 6 is alkyl of 1-6 carbon atoms) to afford the esters of formula
- the other co-reagents necessary to effect the Mitsunobu Reaction include one or more molar equivalents of a alkyl of 1-6 carbon atoms azodicarboxylate diester such as diethyl azodicarboxylate or diisopropyl azodicarboxylate and one or more molar equivalents of triarylphosphine such as triphenylphosphine in a suitable solvent such as diethyl ether, THF, benzene or toluene at temperatures ranging from -20°C to 120°C at temperatures ranging from -20°C to 120°C.
- the 3-hydroxy carboxylic acid ester of formula CH(OH)(R 7 )CH 2 CO 2 R 6 (R 7 is H or alkyl of 1-6 carbon atoms; R 6 is alkyl of 1-6 carbon atoms) are commercially available or can be prepared from commercially available carboxylic acid precursors under standard esterification conditions.
- R 4 is (R)-CH(R 7 )CH 2 CO 2 R 6 ;
- B, D is H, halogen, CN, alkyl of 1-6 carbon atoms, aryl, aralkyl, alkoxy of 1-6 carbon atoms, nitro;
- X is halogen, alkyl of 1-6 carbon atoms, CN, perfluoroalkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy, nitro, alkylsulfanyl of 1-6 carbon atoms, arylsulfanyl, pyridylsulfanyl, 2-N,N-dimethylamino-ethylsulfanyl;
- R 7 is H or alkyl of 1-6 carbon atoms;
- R 6 is alkyl of 1-6 carbon atoms;
- E is S, O
- esters of formula (Iu) include reacting the esters of formula (Iu) with two or more molar equivalents of boron tribromide or boron trichloride in dichloromethane at -78°C to room temperature; two or more molar equivalents hydrobromic acid in acetic acid at 0°C to 50°C; two or more molar equivalents trimethylsilylbromide or trimethylsilyliodide in dichloromethane, carbon tetrachloride or acetonitrile at -78°C to 50°C; two or more molar equivalents lithium iodide in pyridine or quinoline at temperatures from 60° to 250°C.
- esters of formula (Iv: B, D is H, halogen, alkyl of 1-6 carbon atoms; R 5 is H, alkyl of 1-6 carbon atoms, aryl or aralkyl; R 6 is alkyl of 1-6 carbon atoms; E is S, O)
- a halocarbon solvent such as dichloromethane at temperatures ranging from -78 to room temperature
- B, D is H, halogen, alkyl of 1-6 carbon atoms
- R 5 is H, alkyl of 1-6 carbon atoms, aryl or aralkyl
- R 6 is alkyl of 1-6 carbon atoms
- R 8 is H
- E is S, O
- the phenols of formula (Iw: B, D is H, halogen, alkyl of 1-6 carbon atoms; R 5 is H, alkyl of 1-6 carbon atoms, aryl or aralkyl; R 6 is alkyl of 1-6 carbon atoms; R 8 is H; E is S, O) can be alkylated with one or more molar equivalents of an alkylating agent of formula R 8 X (R 8 is alkyl of 1-6 carbon atoms, lower aralkyl and CH 2 CO 2 CH 3 ; X is halogen; E is S, O) and with one or more molar equivalents of an alkali metal carbonate such as potassium carbonate in a polar aprotic solvent such as DMF to afford the alkylated phenol of formula (Iw: B, D is H, halogen, alkyl of 1-6 carbon atoms; R 5 is H, alkyl of 1-6 carbon atoms, aryl or aralkyl; R 6
- esters of formula (Iw: B, D is H, halogen, alkyl of 1-6 carbon atoms; R 5 is H, alkyl of 1-6 carbon atoms, aryl or aralkyl; R 6 is alkyl of 1-6 carbon atoms; R 8 is alkyl of 1-6 carbon atoms, lower aralkyl, CH 2 CO 2 CH 3 ; E is S, O)
- B, D is H, halogen, alkyl of 1-6 carbon atoms; R 5 is H, alkyl of 1-6 carbon atoms, aryl or aralkyl; R 6 is H; R 8 is alkyl of 1-6 carbon atoms, lower aralkyl, CH 2 CO 2 H; E is S, O).
- the conditions to effect these transformations include aqueous base in which one or more molar equivalents of alkali metal hydroxide such as sodium hydroxide is used in water with a co-solvent such as THF, dioxane or a lower alcohol such as methanol or mixtures of THF and a lower alcohol at temperatures ranging from 0°C to 40°C.
- the compounds of formula (Ix: B, D is H, halogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms; X is halogen, alkyl of 1-6 carbon atoms, CN, perfluoroalkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy, R 5 is H, alkyl of 1-6 carbon atoms, aryl or aralkyl; R 6 is H, alkyl of 1-6 carbon atoms) can be transformed into their sulfone derivatives of formula (Iy: n is 2; B, D is H, halogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms; X is halogen, alkyl of 1-6 carbon atoms, CN, perfluoroalkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, aralkoxy, R 5 is H, alkyl of 1-6
- the compounds of this invention are useful in treating metabolic disorders related to insulin resistance or hyperglycemia, typically associated with obesity or glucose intolerance.
- the compounds of this invention are therefore, particularly useful in the treatment or inhibition of type II diabetes.
- the compounds of this invention are also useful in modulating glucose levels in disorders such as type I diabetes.
- This standard pharmacological test procedure assess the inhibition of rat hepatic microsomal PTPase activity using, as substrate, the phosphotyrosyl dodecapeptide corresponding to the 1142-1153 insulin receptor kinase domain, phosphorylated on the 1146, 1150 and 1151 tyrosine residues.
- the procedure used and results obtained are briefly outlined below.
- Rats (Male Sprague-Dawley rats (Charles River, Springfield, NY) weighing 100-150 g, maintained on standard rodent chow (Purina)) are sacrificed by asphyxiation with CO2 and bilateral thoracotomy. The liver is removed and washed in cold 0.85% (w/v) saline and weighed. The tissue is homogenized on ice in 10 volumes of Buffer A and the microsomes are isolated essentially as described by Meyerovitch J, Rothenberg P, Shechter Y, Bonner-Weir S, Kahn CR. Vanadate normalizes hyperglycemia in two mouse models of non-insulin- dependent diabetes mellitus.
- liver homogenate is filtered through silk to remove any remaining tissue debris and then is centrifuged at 10,000xg for 20 minutes at 40C. The supernatant is decanted and centrifuged at 100,000xgfor 60 minutes at 40C.
- the pellet, microsomes and small vesicles is resuspended and lightly homogenized in : 20 mM TRIS-HC1 (pH 7.4), 50 mM 2-mercaptoethanol, 250 mM sucrose, 2 mM EDTA, 10 mM EGTA, 2 mM AEBSF, 0.1 mM TLCK, 0.1 mM TPCK, 0.5 mM benzamidine, 25 ug/ml leupeptin, 5 ug/ml pepstatin A, 5 ug/ml;H5B antipain, 5 ug/ml chymostatin, 10 ug/ml aprotinin (Buffer A), to a final concentration of approximately 850 ug protein/ml. Protein concentration is determined by the Pierce Coomassie Plus Protein Assay using crystalline bovine serum albumin as a standard (Pierce Chemical Co., Rockford, IL).
- the microsomal fraction (83.25 ul) is preincubated for 10 min at 37deg.C with or without test compound (6.25ul) and 305.5 ul of the 81.83 mM HEPES reaction buffer, pH 7.4.
- Peptide substrate, 10.5 ul at a final concentration of 50 uM, is equilibrated to 37deg.C in a LABLINE Multi-Blok heater equipped with a titerplate adapter.
- the preincubated microsomal preparation (39.5 ul) with or without drug is added to initiate the dephosphorylation reaction, which proceeds at 37deg.C for 30 min.
- the reaction is terminated by the addition of 200 ul of the malachite green-ammonium molybdate-Tween 20 stopping reagent (MG/AM/Tw).
- the stopping reagent consists of 3 parts 0.45% malachite green hydrochloride, 1 part 4.2% ammonium molybdate tetrahydrate in 4 N HC1 and 0.5% Tween 20.
- Sample blanks are prepared by the addition of 200 ul MG/AM Tw to substrate and followed by 39.5 ul of the preincubated membrane with or without drug.
- sample absorbances are determined at 650 nm using a platereader (Molecular Devices). Samples and blanks are prepared in quadruplicates. Screening activity of 50 uM (final) drug is accessed for inhibition of microsomal PTPases.
- PTPase activities based on a potassium phosphate standard curve, are expressed as nmoles of phosphate released min/mg protein. Test compound PTPase inhibition is calculated as percent of control. A four parameter non-linear logistic regression of PTPase activities using SAS release 6.08, PROC NLIN, is used for determining IC50 values of test compounds. All compounds were administered at a concentration of 50 ⁇ M. The following results were obtained using representative compounds of this invention.
- This standard pharmacological test procedure assess the inhibition of recombinant rat protein tyrosine phosphatase, PTP1B, activity using, as substrate, the phosphotyrosyl dodecapeptide corresponding to the 1142-1153 insulin receptor kinase domain, phosphorylated on the 1146, 1150 and 1151 tyrosine residues.
- the procedure used and results obtained are briefly described below.
- Human recombinant PTP1B was prepared as described by Goldstein (see Goldstein et al. Mol. Cell. Biochem. 109, 107, 1992). The enzyme preparation used was in microtubes containing 500-700 ⁇ g/ml protein in 33 mM Tris-HCl, 2 mM EDTA, 10% glycerol and 10 mM 2-mercaptoethanol. Measurement of PTPase activity. The malachite green-ammonium molybdate method, as described (Lanzetta et al. Anal. Biochem. 100, 95, 1979) and adapted for a platereader, is used for the nanomolar detection of liberated phosphate by recombinant PTP1B.
- the test procedure uses, as substrate, a dodecaphosphopeptide custom synthesized by AnaSpec, Inc. (San Jose, CA).
- the peptide, TRDIYETDYYRK corresponding to the 1142-1153 catalytic domain of the insulin receptor, is tyrosine phosphorylated on the 1146, 1150, and 1151 tyrosine residues.
- the recombinant rPTPlB is diluted with buffer (pH 7.4, containing 33 mM Tris-HCl, 2 mM EDTA and 50 mM b-mercaptoethanol) to obtain an approximate activity of 1000-2000 nmoles/min/mg protein.
- the diluted enzyme (83.25 mL) is preincubated for 10 min at 37°C with or without test compound (6.25 mL) and 305.5 mL of the 81.83 mM HEPES reaction buffer, pH 7.4 peptide substrate, 10.5 ml at a final concentration of 50 mM, and is equilibrated to 37°C. in a LABLINE Multi-Blok heater equipped with a titerplate adapter.
- the preincubated recombinant enzyme preparation (39.5 ml) with or without drug is added to initiate the dephosphorylation reaction, which proceeds at 37°C for 30 min.
- the reaction is terminated by the addition of 200 mL of the malachite green-ammonium molybdate-Tween 20 stopping reagent (MG/AM/Tw).
- the stopping reagent consists of 3 parts 0.45% malachite green hydrochloride, 1 part 4.2% ammonium molybdate tetrahydrate in 4 N HC1 and 0.5% Tween 20.
- Sample blanks are prepared by the addition of 200 mL MG/AM/Tw to substrate and followed by 39.5 ml of the preincubated recombinant enzyme with or without drug. The color is allowed to develop at room temperature for 30 min. and the sample absorbances are determined at 650 nm using a platereader (Molecular Devices). Sample and blanks are prepared in quadruplicates.
- PTPase activities based on a potassium phosphate standard curve, are expressed as nmoles of phosphate released/min/mg protein. Inhibition of recombinant PTP1B by test compounds is calculated as percent of phosphatase control.
- the non-insulin dependent diabetic (NIDDM) syndrome can be typically characterizes by obesity, hyperglycemia, abnormal insulin secretion, hyperinsulinemia and insulin resistance.
- the genetically obese-hyperglycemic ob/ob mouse exhibits many of these metabolic abnormalities and is thought to be a useful model to search for hypoglycemic agents to treat NIDDM [Coleman, D.: Diabetologia 14: 141-148, 1978].
- mice [Male or female ob/ob (C57 B1/6J) and their lean litermates (ob/+ or +/+, Jackson Laboratories) ages 2 to 5 months (10 to 65 g)] of a similar age were randomized according to body weight into 4 groups of 10 mice. The mice were housed 5 per cage and are maintained on normal rodent chow with water ad libitum. Mice received test compound daily by gavage (suspended in 0.5 ml of 0.5% methyl cellulose); dissolved in the drinking water; or admixed in the diet. The dose of compounds given ranges from 2.5 to 200 mg/kg body weight/day. The dose is calculated based on the fed weekly body weight and is expressed as active moiety.
- mice received vehicle only.
- representative compounds of this invention have been shown to inhibit PTPase activity and lower blood glucose levels in diabetic mice, and are therefore useful in treating metabolic disorders related to insulin resistance or hyperglycemia, typically associated with obesity or glucose intolerance. More particularly, the compounds of this invention useful in the treatment or inhibition of type II diabetes, and in modulating glucose levels in disorders such as type I diabetes. As used herein, the term modulating means maintaining glucose levels within clinically normal ranges.
- Effective administration of these compounds may be given at a daily dosage of from about 1 mg/kg to about 250 mg kg, and may given in a single dose or in two or more divided doses. Such doses may be administered in any manner useful in directing the active compounds herein to the recipient's bloodstream, including orally, via implants, parenterally (including intravenous, intraperitoneal and subcutaneous injections), rectally, vaginally, and transdermally.
- transdermal administrations are understood to include all administrations across the surface of the body and the inner linings of bodily passages including epithelial and mucosal tissues.
- Such administrations may be carried out using the present compounds, or pharmaceutically acceptable salts thereof, in lotions, creams, foams, patches, suspensions, solutions, and suppositories (rectal and vaginal).
- Oral formulations containing the active compounds of this invention may comprise any conventionally used oral forms, including tablets, capsules, buccal forms, troches, lozenges and oral liquids, suspensions or solutions.
- Capsules may contain mixtures of the active compound(s) with inert fillers and/or diluents such as the pharmaceutically acceptable starches (e.g. corn, potato or tapioca starch), sugars, artificial sweetening agents, powdered celluloses, such as crystalline and microcrystalline celluloses, flours, gelatins, gums, etc.
- Useful tablet formulations may be made by conventional compression, wet granulation or dry granulation methods and utilize pharmaceutically acceptable diluents, binding agents, lubricants, disintegrants, suspending or stabilizing agents, including, but not limited to, magnesium stearate, stearic acid, talc, sodium lauryl sulfate, microcrystalline cellulose, carboxymethylcellulose calcium, polyvinylpyrrolidone, gelatin, alginic acid, acacia gum, , xanthan gum, sodium citrate, complex silicates, calcium carbonate, glycine, dextrin, sucrose, sorbitol, dicalcium phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, talc, dry starches and powdered sugar.
- pharmaceutically acceptable diluents including, but not limited to, magnesium stearate, stearic acid, talc, sodium lauryl sulfate, micro
- Oral formulations herein may utilize standard delay or time release formulations to alter the absorption of the active compound(s).
- Suppository formulations may be made from traditional materials, including cocoa butter, with or without the addition of waxes to alter the suppository's melting point, and glycerin.
- Water soluble suppository bases such as polyethylene glycols of various molecular weights, may also be used.
- the dosage, regimen and mode of administration of these compounds will vary according to the malady and the individual being treated and will be subject to the judgment of the medical practitioner involved. It is preferred that the administration of one or more of the compounds herein begin at a low dose and be increased until the desired effects are achieved.
- Example 1 Benzorblthiophene-2-yl-(phenyl -methanol n-Butyl lithium (35 ml, 2.5 N in hexanes) was added dropwise to a stirred solution of thianaphthene (11.5 g, 85.6 mmol) in THF (300 mL) at -78°C under a dry N2 atmosphere. After 1 h , benzaldehyde (9.6 mL, 94.4 mmol ) was added and the cold bath was removed. After an additional 30 minutes, sat. aq. NH4C1 was added and the reaction mixture was partitioned between water and ether. The ether phase was washed with brine and concentrated.
- Example 2 (6-Methoxy-benzo [bl thiophene-2-yl-(pheny 1) -methanol n-Butyl lithium (12.5 ml, 2.5 N in hexanes) was added dropwise to a stirred solution of 6-methoxythianaphthene (5.0 g, 30.4 mmol, S. L. Graham, et al., J. Med. Chem. 1989, 32, 2548-2554) in THF (70 mL) at -78°C under a dry N2 atmosphere. After 1 h , benzaldehyde (3.42 mL, 33.4 mmol ) was added. After an additional 45 minutes, sat. aq.
- Trifluoroacetic acid 105 mL was added dropwise over a 35 minute period to a stirred suspension of benzo[b]thiophene-2-yl-(phenyl)-methanol (17.6 g, 73.2 mmol), sodium borohydride (13.75 g, 364 mmol) and ether (1.3 L). After an additional 5 hours the reaction mixture was added to 10 % aqueous sodium hydroxide (1.3 L) and stirred for 30 minutes. The layers were separated and the ether phase was washed with brine (500 mL) and dried (MgSO4).
- Tin tetrachloride (9.0 mL, 76.91 mmol) was added dropwise over a 25 minute period to a stirred solution of 2-benzyl-benzo[b]thiophene (14.87 g, 96.79 mmol), p- anisoyl chloride (11.75 g, 68.87 mmol) and carbon disulfide (75 mL) under a dry nitrogen atmosphere. After 6 hours, the reaction mixture was added to water and extracted with dichloromethane. The dichloromethane extract was washed with sat. aq. sodium bicarbonate and brine. The solvent was removed and the resultant solid was triturated with pet.
- Tin tetrachloride (2.0 mL, 17.09 mmol) was added dropwise over a 10 minute period to a stirred, -78°C solution of 2-benzyl-6-methoxy-benzo[b]thiophene (2.7 lg, 10.65 mmol), anisoyl chloride (1.93 g, 11.29 mmol) and dichloromethane (41 mL) under a dry nitrogen atmosphere. After 1 hours at -78°C, the reaction mixture was slowly warmed to room temperature and stirred for 16 h period. The reaction mixture was added to water and extracted with ether. The ether phase was washed with brine and silica gel was added to it.
- Tin tetrachloride (3.44 mL, 29.48 mmol) was added dropwise over a 20 minute period. The reaction mixture was warmed to room temperature and stirred overnight. The reaction mixture was added to water and extracted with ether. The ether extract was washed with water and brine. Silica gel was added and the solvent was removed. The adsorbate was flash chromatographed (gradient, petroleum ether to 95:5 petroleum ether : ethyl acetate).
- Neat boron tribromide (4.3 mL, 45.2 mmol) was added dropwise to a stirrred suspension of (2-benzyl-benzo[b]thiophen-3-yl)-(3,5-diisopropyl-4-methoxy-phenyl)- methanone (3.57 g, 8.07 mmol) in dichloromethane (30 mL) at -78°C under a dry nitrogen atomosphere. The solution was allowed to warm to ambient temperature and was stirred for 1.5 h. The reaction mixture was cooled to 0°C and carefully quenched with water . The reaction mixture was partitioned between water and ether. The ether phase was washed with water and brine.
- reaction mixture was quenched with water (100 mL), diluted with methylene chloride (50 mL) and the organics were extracted with diethyl ether (1x100 mL, 1x75 mL). The extracts were combined, washed with brine, and combined with silica gel.
- Example 27 Prepared from 4-(benzo[b]naphtho[2,3-d]thiophen-l l-yl)-2-iodo-phenol (Example 27) according to the procedure on Example 22.
- White solid mp 274- 275°C: MS (El): [M+], 466 (100%, MI); Anal. Calc. for C23H15IOS: C, 59.24, H, 3.24, N, 0.00. Found: C, 58.53, H, 3.11 , N, 0.11.
- Example 30 Example 30.
- Example 29 Prepared from 1 l-(3-iodo-4-methoxy-phenyl)-benzo[b]naphtho[2,3-d]thio- phene (Example 29) according to the procedure on Example 30.
- White solid mp 230- 232 °C: MS (El): [M+], 365 (100%, MI); Anal. Calc. for C24H15NOS: C, 78.88, H, 4.41, N, 3.83. Found: C, 77.61, H, 4.23, N, 4.10.
- Example 30 Prepared from 5-benzo[b]naphtho[2,3-d]thiophen-l l-yl-2-methoxy-iso- phthalonitrile (Example 30) according to the procedure on Example 20.
- White solid mp 274-276 °C: MS (El): [M+], 376 (80%, MI);
- Example 31 Prepared from 5-(benzo[b]naphtho[2,3-d]thiophen-l l-yl)-2-methoxy-benzo- nitrile (Example 31) according to the procedure on Example 20.
- White solid mp 231- 232 °C: MS (El): [M+], 351 (100%, MI); Anal. Calc. for C23H13NOS: C, 78.61, H, 3.73, N, 3.99. Found: C, 78.27, H, 3.59, N, 3.89.
- Acetic anhydride (0.62 mL, 6.57 mmol) was added to a 0°C, stirred solution of 4-benzo[b]naphtho[2,3-d]thiophen-l l-yl-phenol (2.0 g, 6.13 mmol) in pyridine (8 mL).
- Example 18 according to the procedure of Example 34.
- White solid mp 179-180°C: MS (El): [M+], 426; Anal. Calc. for C26H18O4S: C, 73.22, H, 4.25, N, 0.00. Found: C, 73.17, H, 4.30, N, 0.12.
- Example 37
- Example 35 Prepared from acetic acid 3-benzo[b]naphtho[2,3-d]thiophen-l l-yl)-phenyl ester (Example 35) according to the procedure of Example 37.
- Example 36 Prepared from acetic acid 2-acetoxy-4-(benzo[b]naphtho[2,3-d]thiophen-l l- yl)-phenyl ester (Example 36) according to the procedure of Example 37.
- Example 40 Example 40.
- Methanesulfonic acid 4-Benzo[b]naphthor2,3-d1thiophen-l l-yI-phenyl Ester Methylsulfonyl chloride (0.63 mL, 8.14 mmol) was added dropwise to a cold
- Methanesulfonic acid 4-(6-Iodo-benzo[b]naphthoF2.3-dlthiophen-l l-yl)-phenyl ester To a solution of methanesulfonic acid 4-benzo[b]naphtho[2,3-d]thiophen-l l- yl-phenyl ester (2.24 g, 5.54 mmole) in tetrahydrofuran (22.4 mL), 80% aqueous acetic acid (11.2 mL) and sulfuric acid (0.6 mL) was added iodine (0.984 g, 3.87 mmol) and iodic acid (0.244 g, 1.39 mmol).
- Methanesulfonic acid 4-(6-trifluoromethyl-benzo[blnaphtho[2.3-d1thiophen-l 1-ylV phenyl ester
- Methanesulfonic acid 4-(6-methyl-benzorblnaphtho[2.3-dlthiophen-l 1-vD-phenyl ester A suspension of methanesulfonic acid 4-(6-iodo-benzo[b]naphtho[2,3- d]thiophen-l l-yl)-phenyl ester (1.65g, 3.11 mmole), tetramethyltin (3.58, 25.8 mmole), and bis(triphenyl ⁇ hosphine)palladium II chloride (0.218g, 0.311 mmole 10 mole %) in dry N,N dimethylformamide (16mL) was heated in a sealed vessel under argon at 103°C for 4 hours and left at room temperature overnight.
- a biphasic mixture of methanesulfonic acid 4-(6-chloro-benzo[b]naphtho[2,3- d]thiophen-l l-yl)-phenyl ester (0.917 g, 2.09 mmol) in dioxane (13 mL) and a solution of sodium hydroxide (2.5 N, 6.7 mL, 16.7 mmol, 8 eq) was heated at reflux overnight. After cooling to room temperature the reaction mixture was combined with water (50 mL), acidified with concentrated hydrochloric acid, and stirred for 15 minutes. The crude white solid product was collected by filtration, redissolved in ether, combined with silica gel, and the solvent was removed.
- Example 48 Prepared from methanesulfonic acid 4-(6-trifluoromethyl-benzo[b]naphtho- [2,3-d]thiophen-l l-yl)-phenyl ester (Example 48) according to the procedure of Example 51.
- Example 49 Prepared from methanesulfonic acid 4-(6-methyl-benzo[b]naphtho[2,3-d]thio- phen-l l-yl)-phenyl ester (Example 49) according to the procedure of Example 51.
- reaction mixture was heated at reflux for approximately 3 hours, cooled to room temperature, diluted with water (400 mL), acidified with 10% hydrochloric acid and extracted with diethyl ether. The extracts were combined, silica gel was added and the solvent removed.
- Example 58 l l-(3, 5-Dibromo-4-hydroxy-phenylVbenzo[b1naphthor2.3-d]thiophene-6-carbonitriIe
- acetic acid 3 mL
- Example 59-66 The compounds in Examples 59-66 were prepared using the procedure in Example 58 and the appropriate starting material. Example 59.
- the layers were separated and silica gel was added to the ether phase.
- the ether was removed and the adsorbate was flashed (gradient: 9: 1 to 1: 1 petroleum ethe ⁇ ethyl acetate).
- Silica gel was added to the fractions containing the desired product and the solvent was removed.
- the adsorbate was flashed (9: 1 petroleum ethe ⁇ ethyl acetate).
- Silica gel was added to the fractions containing the desired product and the solvent was removed.
- reaction mixture was diluted with water and extracted with ether (100 mL).
- the aqueous phase was acidified with 10% aqueous HCl and filtered.
- the solid was washed with water and triturated with pet. ether.
- the solid was dried in vacuo at 70°C to provide a grey solid.
- Example 76 ri l-(4-Carboxymethoxy-phenyl ' )-benzo[b1naphthor2.3-d1thiophen-8-yloxyl-acetic acid
- methyl ester 0.268 g, 0.551 mmol
- tetrahydrofuran 8 mL
- methanol 5 mL
- reaction mixture was concentrated, water (2.5 mL) was added and the solid was filtered (101 mg) .
- the aqeous phase was extracted with ether (25 mL) and the ether phase was evaporated to dryness to provide a second solid (77 mg).
- the ethyl acetate extract was washed with water, dried with brine and anhydrous MgSO4, and concentrated to provide a white solid.
- the solid was dissolved in ethyl acetate (60 mL) and silica gel was added. Solvent was removed and the adsorbate was flash chromatographed (eluent 7:3 petroleum ether: ethyl acetate) to provide the methyl ester as a white solid (0.195 g, 42%).
- Aqueous potassium carbonate (124 mg in 4 mL of water, 0.90 mmol) was added to a stirred solution of this methyl ester (0.190 g, 0.45 mmol) in THF (5 mL) at ambient temperature.
- Example 84-95 The compounds in Examples 84-95 were prepared using the procedure in Example 83 and the appropriate starting material.
- Example 84 r4-Benzorb]naphthol2.3-d1thiophen-l 1-yl-phenoxyl -acetic acid From 4-benzo[b]naphtho[2,3-d]thiophen-l 1-yl-phenol (Example 14).
- Example 86 f 2.6-Dimethyl-4-r6-methyl-(benzo[b]naphthor2.3-dlthiophen-l l-yl 1-phenoxyl- acetic acid From ⁇ 2,6-dimethyl-4-[6-methyl-(benzo[b]naphtho[2,3-d]thiophen- 11-yl)]- phenoxy] -acetic acid methyl ester (Example 25).
- Example 87 r4-(6-Bromo-benzo[b]naphtho[2.3-dlthiophen-l l-yl)-phenoxyl-acetic acid From [4-(6-bromo-benzo[b]naphtho[2,3-d]thiophen-l l-yl)-phenoxy]-acetic acid, methyl ester ester (Example 41).
- N-t-BOC-L- ⁇ -Imidazolelactic acid, methyl ester Triethylamine (0.878 mL, 6.3 mmol) was added dropwise to a stirred, ambient temperature solution of L- ⁇ -imidazolelactic acid, methyl ester, hydrochloride (0.87 g, 4.2 mmol) in methanol (12 mL) under a dry nitrogen atmosphere. The stirring was continued at ambient temperature for 40 min. After 6 h., the reaction mixture was concentrated to yield an oil and dichloromethane (150 mL) was added. The dichloromethane was washed with water and brine. Silica gel (12 mL) was added.
- Example 104 3-Pyridin-3-yl-propionic acid, ethyl ester
- Trifluoroacetic anhydride (1.1 mL, 7.66 mmol) was added dropwise to a stirred suspension of (s)-(+)- ⁇ ,3-dihydroxy-l-oxo-2-isoindolinebutyric acid, methyl ester (0.84 g, 3.19 mmol) in chloroform (10 mL) under a try N2 atmosphere for 2 hours. After the reaction mixture was concentrated to yield an oil, trifluoroacetic acid (3.4 mL) and triethylsilane (1.1 mL, 3.83 mmol) were added at ambient temperature under a dry nitrogen atmosphere. After 6 hours, the reaction mixture was carefully quenched with 10% aqueous sodium bicarbonate.
- Diethylazodicarboxylate (0.437 mL, 2.74 mmol) was added dropwise to a stirred, room temperature suspension of 2,6-dibromo-4-(6-bromo-benzo[b]naphtho- [2,3-d]thiophen-l l-yl)-phenol ( 1.00 g, 1.83 mmol), (S)-2-hydroxy-3-phenylpropionic acid, methyl ester (0.494 g, 2.74 mmol), triphenylphosphine (0.72 g, 2.74 mmol) and benzene (12 mL) under a dry nitrogen atmosphere. Dissolution occurred and the solution was heated in an 80°C oil bath for 3.5 h.
- Diethylazodicarboxylate (0.839 mL, 5.50 mmol) was added dropwise to a stirred, room temperature suspension of 2,6-dibromo-4-(6-bromo-benzo[b]naphtho- [2,3-d]thiophen-l l-yl)-phenol (2.00 g, 3.55 mmol), (R)-2-hydroxy-3-phenylpropionic acid, methyl ester (0.96 g, 5.50 mmol), triphenylphosphine (1.40 g, 5.50 mmol) and benzene (15 mL) under a dry nitrogen atmosphere. Dissolution occurred and the solution was heated in an 80°C oil bath for 19 h.
- Diethylazodicarboxylate (DEAD, 0.210 mL, 1.33 mmol) was added to a stirred, room temperature solution of 2,6-dibromo-4-(6-bromo-benzo[b]naphtho[2,3- d]thiophen-l l-yl)-phenol ( 0.500 g, 0.888 mmol), (S)-2-hydroxy-4-phenyl-butyrate, ethyl ester (0.277 g, 1.33 mmol), triphenylphosphine (0.350 g, 1.33 mmol) and benzene (3.8 mL) under a dry nitrogen atmosphere. Dissolution occurred and the solution was heated in an 80°C oil bath for 2 h.
- reaction mixture Upon cooling to room temperature, the reaction mixture was diluted with ether and silica gel was added. The reaction mixture was concentrated and the silica adsorbate was flash chromatographed (95 : 5 petroleum ether : ethyl acetate) to provide a white solid (0. 570 g, 85%). Aqueous potassium hydroxide (1 N, 1.4 mL, 1.4 mmol) was added to a stirred solution of this solid (0.562 g, 0.746 mmol) in THF (12 mL)/methanol (5 mL). After 3h the solution was concentrated, diluted with water and acidified with 10% aqueous HCl.
- Examples 114-144 were prepared using the procedure in Example 113 and the appropriate starting materials.
- Diethylazodicarboxylate (0.293 mL, 1.86 mmol) was added dropwise to a stirred, ambient temperature suspension of 2,6-dibromo-4-(6-bromo-benzo[b]- naphtho[2,3-d]thiophen-l l-yl)-phenol (0.700 g, 1.24 mmol), (S)-(+)-2-hydroxy-l,3- dioxo-2-isoindolinebutyric acid, methyl ester (0.490 g, 1.86 mmol), triphenylphosphine (0.488 g, 1.86 mmol) and benzene (5.5 mL) under a dry nitrogen atmosphere.
- reaction mixture was quenched with 10% aqueous sodium bisulfide and further diluted with water (100 mL). Aqueous mixture was extracted with ethyl acetate (150 mL). The ethyl acetate extract was washed with water, dried with brine and anhydrous MgSO4, and concentrated to provide a white solid.
- Diethylazodicarboxylate (DEAD, 0.133 mL, 0.845 mmol) was added to a stirred, room temperature solution of l l-(4-hydroxy-phenyl)-benzo[b]naphtho[2,3- d]thiophen-3-yloxy]-acetic acid methyl ester ( 0.140 g, 0.338 mmol), L-3-phenyllactic acid, methyl ester (0.133 g, 0.845 mmol), triphenylphosphine (0.222 g, 0.845 mmol) and benzene (1.5 mL) under a dry nitrogen atmosphere. Dissolution occurred and the solution was heated in an 80°C oil bath for 6 h.
- This solid was recrystalized from acetonitrile containing 0.1% of trifluoroacetic acid to provide a white solid (144 mg).
- 1.0 M solution of boron tribromide (1.4 mL, 1.4 mmol) in dichloromethane was added to a stirred, -78°C solution of this solid in dichloromethane (3. 0 mL). After 45 min the reaction mixture was warmed to room temperature.
- Afer 3.5 h the reaction mixture was recooled to -78°C and an additional amount of 1.0N boron tribromide (0.8 mL, 0.8 mmol) was added. The reaction mixture was warmed to room temperature.
- Example 150 (RV2-[4-(6-Bromo-benzorblnaphthoI2.3-d1thiophen-l l-ylVphenoxy1-4-(l. 3-dioxo-l. 3-dihydro-isoindol-2-ylVbutyric acid
- Diethylazodicarboxylate (0.254 mL, 1.61 mmol) was added dropwise to a stirred, room temperature suspension of 2,6-dibromo-4-(6-bromo-benzo[b]naphtho- [2,3-d]thiophen-l l-yl)-phenol ( 0.600 g, 1.10 mmol), dimethyl (S)-(-)-malate (0.213 mL, 1.61 mmol) and triphenylphosphine (0.421 g, 1.61 mmol) in benzene (7.5 mL) under a dry nitrogen atmosphere. The solution was heated in an 79°C oil bath for 23 h.
- Diisopropylamine (distilled over CaH2, 0.169 mL, 1.2 mmol) was added to anhydrous tetrahydrofuran (0.65 mL) and cooled to -74°C under a dry argon atmosphere.
- n-Butyllithium (2.5M in hexane, 0.516 mL, 1.29 mmole) was added dropwise and the mixture was warmed to 0°C for 10 minutes then recooled to -74°C.
- Hexamethylphosphoramide (0.83 mL) was added followed 5 minutes later by the slow (0.5 hour) dropwise addition of a solution of (R)-2-[2,6-dibromo-4-(6-bromo- benzo[b]naphtho[2,3-d]thiophen-l l-yl)-phenoxy]-propionic acid, tert-butyl ester (0.715g, 1.06 mmole) in anhydrous tetrahydrofuran (2.8 mL). After stiring one hour at -75°C, 4-fluorobenzylbromide (0.158 mL, 1.29 mmol) was added dropwise.
- reaction mixture After stirring 1 hour at -80°C the reaction mixture was allowed to warm to room temperature overnight. The reaction mixture was quenched with dilute aqueous ammonium chloride and was partitioned between water (100 mL) and a 1 : 1 methylene chloride : ether solution (130 mL). After one more extraction with methylene chloride (50mL) the organic layers were combined, silica gel was added, and the solvents removed.
- reaction mixture After stirring 0.5 hour at -80°C the reaction mixture was allowed warm to room temperature overnight. The reaction mixture was quenched with dilute aqueous ammonium chloride and was partritioned between water (100 mL) and a 1 : 1 methylene chloride : ether solution (200 mL).
- Example 159 r4-(Benzo[b1naphtho[2.3-dlthiophen-l l-yl)-phenoxymethy 11 -phosphonic acid diethyl ester
- a solution of 4-(benzo[b]naphtho[2,3-d]thiophen-l 1-yl-phenol (1.00 g, 3.06 mmol) in THF (5 mL) was added dropwise to a stirred, 0°C solution of 80 % sodium hydride (0.138 g, 4.95 mmol) in THF (10 mL) under a dry nitrogen atmosphere over a period of 15 min.
- Diethylazodicarboxylate (0.420 mL, 2.67 mmol) was added dropwise to a stirred, ambient temperature suspension of 2,6-dibromo-4-(6-bromo-benzo[b]- naphtho[2,3-d]thiophen-l l-yl)-phenol (1.00 g, 1.78 mmol), 3 -phenyl- 1 -hydro- 1- propylphosphonic acid, diethyl ester (0.730 g, 2.67 mmol), triphenylphosphine (0.700 g, 2.67 mmol) and benzene (9 mL) under a dry nitrogen atmosphere. The solution was heated in an 80°C oil bath for 4 h.
- the solid was filtered and partitioned in ethyl acetate (100 mL) and 20 % aquous HCl (60 mL) with stirring for 3 h.
- the solid was filtered ,washed with water and triturated with pet. ether.
- reaction mixture was added to water and partitioned between water/ethyl acetate and THF.
- Silica gel was added to the organic phase and the solvent was removed.
- the adsorbate was flashed (7:3, petroleum:ethyl acetate) to provide an off-white solid (2.23 g). This solid was dissolved in dichloromethane and silica gel was added.
- Trifluoroacetic anhydride (0.375, 2.65 mmol) was added to a stirred, room temperature suspension of (R)-2-[2,6-dibromo-4-(6-bromo-benzo[b]naphtho[2,3- d]thiophen-l l-yl)-phenoxy]-3-phenyl-propionamide (1.68 g, 2.37 mmol), pyridine (0.393 mL, 4.74 mmol) and dioxane (5.4 mL). Dissolution occurred and the solution was heated in a 105°C oil bath for 2h. The reaction mixture was cooled to room temperature, diluted with ether, washed with 5% HCl and brine.
- Trimethylaluminum (2.55 mL, 3.84mmol, 2.0 M solution in toluene) was added to [2,6-dibromo-4-(6-bromo-benzo[b]naphtho[2,3-d]thiophen-l l-yl)-phenoxy]- acetonitrile (0.615 g, 1.02 mmol) under a dry nitrogen atmosphere.
- Trimethylsilyl azide 0.510 mL, 3.84 mmol
- Trimethylaluminum (7.24 mL, 14.4 mmol, 2.0 M solution in toluene) was added to (R)-2-[2,6-dibromo-4-(6-bromo-benzo[b]naphtho[2,3-d]thiophen-l l-yl)- phenoxy]-3-phenyl-propionamide (1.33 g, 1.93 mmol) under a dry nitrogen atmosphere. Trimethylsilyl azide (1.92 mL, 14.4 mmol) was then added and the solution was heated in a 85 °C oil bath. After 7h the reaction mixture was cooled to room temperature and diluted with ether.
- Lithium (bis)trimethylsilylamide (1.0 M in THF, 5.32 mL, 5.32 mmol) was added dropwise over a 20 min period to a -78°C stirred solution of 2,6-dibromo-4-(6- bromo-benzo[b]naphtho[2,3-d]thiophen-l l-yl)-phenol (1.50 g, 2.66 mmol), 5- bromothiazolidine dione (Zask, et al., J. Med Chem, 1990, 33, 1418-1423, 0.522 g, 2.66 mmol) and THF (20 mL) under a dry nitrogen atmosphere. After 45 min, the reaction mixture was warmed to room temperature.
- Phosphoric acid Di-tert-Butyl ester 2.6-Dibromo-4-(6-bromo-benzo[b1naphthor2.3- dlthiophen-1 l-yl)-phenyl ester Tetrazole (0.215 g, 3.0 mmol) was added in one portion to a stirred suspension of 2,6-dibromo-4-(6-bromo-benzo[b]naphtho[2,3-d]thiophen-l l-yl)-phenol (0.527 g, 1.0 mmol), di-tert-butyl N,N-diethyhlphosporamidate (93%, 0.353 mL, 1.0 mmol) in THF at room temperature under a dry nitrogen atmosphere.
- Solid sodium hydroxide (0.682 g, 17.05 mmol) was added in three equal portions to a 0°C, stirred suspension of 2,6-dibromo-4-(6-bromo-benzo[b]naphtho- [2,3-d]thiophen-l l-yl)-phenol (0.800 g, 1.421 mmol), l,l,l-trichloro-2-methyl-2- propanol tetrahydrate (1.06 g, 4.263 mmol) in acteone (7.5 mL) over 3 h period.
- the resulting suspension was warmed to room temperature and stirred for 15 h.
- the reaction mixture was added to water, acidified with 10% aqueous HCl and extracted with ether.
- To the ether phase was added acid washed (2% phosphoric acid in methanol) silica gel and the solvent was removed.
- reaction mixture was added to water, acidified with 10% aqueous HCl and extracted with ethyl acetate. To the ethyl acetate phase was added acid washed (2% phosphoric acid in methanol) silica gel and the solvent was removed.
- the reaction mixture was added to water and extracted with ethyl acetate.
- the ethyl acetate layer was washed with aqueous IN Hcl, sat. sodium bicarbaonte and dried *(magnesium sulfate).
- the ethyl acetate was removed and and the crude product was flash chromatographed (95:5 ethyl acetate: pet. ether) to provide (5'-benzo[b]naphtho[2,3-d]thiophen-l l-yl)-[l,l ';3',l"]- terphenyl-2'-yloxy)-acetic acid, methyl ester as a white solid (0.177 g).
- Aqueous potassium hydroxide (1 N, 1.61 mL, 1.61 mmol) was added to a stirred solution of this methyl ester in 3:2 THF:methanol (5.0 mL) at ambient temperature. After 2 h the solution was concentrated, diluted with water (75 mL) and acidified with 10% aqueous HCl.
- Benzyl bromide (0.093 mL, 0.78 mmol) was added dropwise to this mixture over a period of ten minutes. After the mixture was stirred at 0 °C for 6.5 h., the reaction mixture was quenched with aqueous hydrochloric acid to pH 1 and further diluted with water (60 mL) and aqueous mixture was extracted with methylene chloride (2 X 60 mL). The combined organic extracts were washed with water and dried with brine. Silica gel (5 mL) was added.
- Iodomethane (0.086 mL, 1.38 mmol) was added dropwise to a room temperature, stirred light suspension of a mixture [3-bromo-5-(6-bromo-benzo[b]- naphtho[2,3-d]thiophen-l l-yl)-2-benzyloxy-phenol (87% pure, contaminated with 2-bromo-4-(6-bromo-benzo[b]naphtho[2,3-d]thiophen- 11 -yl)-6-benzyloxy-phenol (13%), 0.271 g, 0.46 mmol), potassium carbonate (0.191 g, 1.38 mmol) in DMF (2 mL) over a period of twenty minutes.
- reaction mixture was quenched with aqueous hydrochloride to pH 1 and further diluted with water (40 mL) and aqueous mixture was extracted with methylene chloride (80 mL).
- Iodomethane (0.074 mL, 1.2 mmol) was added dropwise to a rt, stirred light suspension of 3-bromo-5-(6-bromo-benzo[b]naphtho[2,3-d]thiophen-l l-yl)-benzene- 1,2-diol (0.30 g, 0.60 mmol), potassium carbonate (0.083 g, 0.6 mmol) in DMF (1.5 mL) over a period of five minutes.
- reaction mixture was quenched with aqueous hydrochloric acid to pH 1 and further diluted with water (80 mL) and aqueous mixture was extracted with methylene chloride (120 mL). The organic extract was washed with water and dried with brine. Silica gel (5 mL) was added.
- Example 201 r3-(6-Bromo-benzo[blnaphthor2.3-d1thiophen- 11 -yl)-2.6-difluoro-phenoxyl-acetic acid
- 3-(6-bromo-benzo[b]naphtho[2,3-d]thiophen-l l-yl)-2,6 difluoro-phenol (0.200 g, 0.453 mmol) and potassium carbonate (0.085, 0.612 mmol) in N,N-dimethylformamide (2 mL) was added methyl bromoacetate (0.086 mL, 0.906 mmol) dropwise at room temperature under a dry nitrogen atmosphere.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7659298A | 1998-05-12 | 1998-05-12 | |
US76592 | 1998-05-12 | ||
PCT/US1999/010185 WO1999058521A1 (fr) | 1998-05-12 | 1999-05-10 | 11-ARYL-BENZO[B]NAPHTO[2,3-D]FURANES ET 11-ARYL-BENZO[b]NAPHTO[2,3-d]THIOPHENES UTILES DANS LES TRAITEMENTS DE LA RESISTANCE INSULINIQUE ET DE L'HYPERGLYCEMIE |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1077970A1 true EP1077970A1 (fr) | 2001-02-28 |
Family
ID=22133016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99922897A Withdrawn EP1077970A1 (fr) | 1998-05-12 | 1999-05-10 | 11-ARYL-BENZO B]NAPHTO 2,3-D]FURANES ET 11-ARYL-BENZO b]NAPHTO 2,3-d]THIOPHENES UTILES DANS LES TRAITEMENTS DE LA RESISTANCE INSULINIQUE ET DE L'HYPERGLYCEMIE |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1077970A1 (fr) |
JP (1) | JP2002514638A (fr) |
CN (1) | CN1308627A (fr) |
AU (1) | AU3979199A (fr) |
CA (1) | CA2330623A1 (fr) |
WO (1) | WO1999058521A1 (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6281238B1 (en) * | 1998-05-12 | 2001-08-28 | American Home Products Corporation | 4-aryl-1-oxa-9-thia-cylopenta[B]fluorenes |
US6498182B2 (en) | 2000-09-26 | 2002-12-24 | Biovitrum Ab | Compounds |
CA2437118A1 (fr) | 2001-02-09 | 2002-08-22 | Merck & Co., Inc. | Acides 2-aryloxy-2-arylalcanoiques utilises pour le traitement du diabetes et des troubles lipidiques |
DE10140148B4 (de) | 2001-08-16 | 2012-07-19 | Merck Patent Gmbh | Fluorierte Polycyclen und ihre Verwendung in Flüssigkristallmischungen und in Flüssigkristalldisplays |
CA2469228A1 (fr) | 2001-12-03 | 2003-06-12 | Japan Tobacco Inc. | Compose azole et utilisation medicinale de celui-ci |
BR0308537A (pt) * | 2002-03-20 | 2005-02-09 | Metabolex Inc | Composto, composição, e métodos para tratar diabetes tipo 2 e hiperuricemia, para modular resistência a insulina e para aliviar hiperlipidemia em um indivìduo e agente de prodroga |
CN100532374C (zh) | 2002-10-23 | 2009-08-26 | 格兰马克药品有限公司 | 可用于治疗炎性和变应性病症的新的三环化合物:它们的制备方法以及包含它们的药物组合物 |
PT1620429E (pt) | 2003-04-11 | 2009-04-28 | Glenmark Pharmaceuticals Sa | Novos compostos heterocíclicos úteis para o tratamento de perturbações inflamatórias e alérgicas: processo para a sua preparação e composições farmacêuticas que os contêm |
GB0311406D0 (en) | 2003-05-17 | 2003-06-25 | Queen Mary & Westfield College | Substituted phosphonate fluorescent sensors,and use thereof |
WO2004106542A1 (fr) | 2003-05-29 | 2004-12-09 | Sankyo Company, Limited | Compose resistant a l'insuline et methode de criblage de celui-ci |
US7371759B2 (en) | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
US7141596B2 (en) | 2003-10-08 | 2006-11-28 | Incyte Corporation | Inhibitors of proteins that bind phosphorylated molecules |
US7420059B2 (en) | 2003-11-20 | 2008-09-02 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
WO2006011024A2 (fr) * | 2004-07-19 | 2006-02-02 | Glenmark Pharmaceuticals Ltd. | Nouveaux composes tricycliques utilises dans le traitement de troubles inflammatoires et allergiques, procede de preparation associe, et compositions pharmaceutiques les contenant |
PL1831227T3 (pl) | 2004-12-17 | 2013-10-31 | Glenmark Pharmaceuticals Sa | Nowe związki heterocykliczne użyteczne w leczeniu stanów zapalnych i dolegliwości alergicznych |
ES2417491T3 (es) | 2004-12-17 | 2013-08-08 | Glenmark Pharmaceuticals S.A. | Novedosos compuestos heterocíclicos útiles para el tratamiento de trastornos inflamatorios y alérgicos |
GB0708507D0 (en) | 2007-05-02 | 2007-06-13 | Queen Mary & Westfield College | Substituted phosphonates and their use |
DK2170930T3 (da) | 2007-06-04 | 2012-11-05 | Synergy Pharmaceuticals Inc | Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
JP2011522828A (ja) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
GB0822486D0 (en) | 2008-12-10 | 2009-01-14 | Univ Liverpool | Compounds for use in the treatment of pain |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
WO2014057522A1 (fr) | 2012-10-12 | 2014-04-17 | Mochida Pharmaceutical Co., Ltd. | Compositions et procédés de traitement de la stéatohépatite non alcoolique |
AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
US10441560B2 (en) | 2013-03-15 | 2019-10-15 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
SG11201507288UA (en) | 2013-03-15 | 2015-10-29 | Mochida Pharm Co Ltd | Compositions and methods for treating non-alcoholic steatohepatitis |
KR102272746B1 (ko) | 2013-06-05 | 2021-07-08 | 보슈 헬스 아일랜드 리미티드 | 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2750426B1 (fr) * | 1996-06-28 | 1998-08-07 | Cird Galderma | Nouveaux composes biaryles heterocycliques et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetique |
-
1999
- 1999-05-10 WO PCT/US1999/010185 patent/WO1999058521A1/fr not_active Application Discontinuation
- 1999-05-10 CN CN99808422A patent/CN1308627A/zh active Pending
- 1999-05-10 JP JP2000548325A patent/JP2002514638A/ja active Pending
- 1999-05-10 AU AU39791/99A patent/AU3979199A/en not_active Abandoned
- 1999-05-10 EP EP99922897A patent/EP1077970A1/fr not_active Withdrawn
- 1999-05-10 CA CA002330623A patent/CA2330623A1/fr not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO9958521A1 * |
Also Published As
Publication number | Publication date |
---|---|
CN1308627A (zh) | 2001-08-15 |
CA2330623A1 (fr) | 1999-11-18 |
WO1999058521A1 (fr) | 1999-11-18 |
JP2002514638A (ja) | 2002-05-21 |
AU3979199A (en) | 1999-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999058521A1 (fr) | 11-ARYL-BENZO[B]NAPHTO[2,3-D]FURANES ET 11-ARYL-BENZO[b]NAPHTO[2,3-d]THIOPHENES UTILES DANS LES TRAITEMENTS DE LA RESISTANCE INSULINIQUE ET DE L'HYPERGLYCEMIE | |
AU756337B2 (en) | Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia | |
US6444670B2 (en) | Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin-resistance and hyperglycemia | |
US6166069A (en) | Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia | |
EP1077967B1 (fr) | Acides biphenyl-oxo-acetiques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie | |
US6232322B1 (en) | Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia | |
KR100190673B1 (ko) | 벤조푸란, 벤조 티오펜, 인돌 및 인돌리진의 유도체, 그것들의 제조방법 및 그것들을 함유한 조성물 | |
EP1077965A1 (fr) | Acides phenyl-oxo-acetiques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie | |
US6110962A (en) | 11-aryl-benzo[B]naphtho[2,3-D]furans and 11-aryl-benzo[B]naphtho[2,3-D]thiophenes useful in the treatment of insulin resistance and hyperglycemia | |
EP1077968A1 (fr) | Derives de naphto[2,3-b]heteroar-4-yle | |
US6248764B1 (en) | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia | |
US6057316A (en) | 4-aryl-1-oxa-9-thia-cyclopenta[b]fluorenes | |
US6001867A (en) | 1-aryl-dibenzothiophenes | |
US6121271A (en) | Naphtho[2,3-B]heteroar-4-yl derivatives | |
US6340676B2 (en) | 4-aryl-1-oxa-9-thia-cyclopenta (b) fluorenes | |
MXPA00011089A (en) | 11-aryl-benzo[b]naphtho[2,3-d]furans and 11-aryl-benzo[b]naphtho[2,3-d]thiophenes useful in the treatment of insulin resistance and hyperglycemia | |
MXPA00011091A (en) | Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia | |
CZ20004182A3 (cs) | Deriváty benzothiofenu, benzofuranu a indolu | |
MXPA00011086A (en) | Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20001024 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL PAYMENT 20001024;LT PAYMENT 20001024;LV PAYMENT 20001024;RO PAYMENT 20001024;SI PAYMENT 20001024 |
|
17Q | First examination report despatched |
Effective date: 20010717 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: WYETH |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20030211 |